[go: up one dir, main page]

WO2005049023A1 - Glyt1 transporter inhibitors - Google Patents

Glyt1 transporter inhibitors Download PDF

Info

Publication number
WO2005049023A1
WO2005049023A1 PCT/EP2004/013052 EP2004013052W WO2005049023A1 WO 2005049023 A1 WO2005049023 A1 WO 2005049023A1 EP 2004013052 W EP2004013052 W EP 2004013052W WO 2005049023 A1 WO2005049023 A1 WO 2005049023A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
piperidin
dimethyl
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/013052
Other languages
French (fr)
Inventor
Steven Coulton
Martin Leonard Gilpin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of WO2005049023A1 publication Critical patent/WO2005049023A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to glycine transporter inhibiting compounds, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.
  • the invention further comprises processes to make these compounds and pharmaceutical formulations thereof.
  • GlyT1 is found predominantly in the forebrain and its distribution corresponds to that of glutaminergic pathways and NMDA receptors (Smith, et. al., Neuron, 8, 1992: 927-935).
  • GlyT-la is found predominantly in the forebrain and its distribution corresponds to that of glutaminergic pathways and NMDA receptors (Smith, et. al., Neuron, 8, 1992: 927-935).
  • GlyT-la three variants of GlyT1 , termed GlyT-la, GlyT-1 b and GlyT-1 c (Kim et al., Molecular Pharmacology, 45, 1994: 608-617), each of which displays a unique distribution in the brain and peripheral tissues.
  • GlyT2 in contrast, is found predominantly in the brain stem and spinal cord, and its distribution corresponds closely to that of strychnine-sensitive glycine receptors (Liu et al., J. Biological Chemistry, 268, 1993: 22802-22808; Jursky and Nelson, J. Neurochemistry, 64, 1995 : 1026-1033).
  • Another distinguishing feature of glycine transport mediated by GlyT2 is that it is not inhibited by sarcosine as is the case for glycine transport mediated by GlyT1.
  • NMDA receptors are critically involved in memory and learning (Rison and Staunton, Neurosci. Biobehav. Rev.. 19 533-552 (1995); Danysz et al, Behavioral Pharmacol.. 6 455-474 (1995)); and, furthermore, decreased function of NMDA-mediated neurotransmission appears to underlie, or contribute to, the symptoms of schizophrenia (Olney and Farber, Archives General Psychiatry, 52, 998-1007 (1996).
  • agents that inhibit GlyT1 and thereby increase glycine activation of NMDA receptors can be used as novel antipsychotics and anti-dementia agents, and to treat other diseases in which cognitive processes are impaired, such as attention deficit disorders and organic brain syndromes.
  • NMDA receptors have been implicated in a number of disease states, in particular the neuronal death associated with stroke and possibly neurodegenerative diseases, such as Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis or other conditions in which neuronal cell death occurs, such as stroke or head trauma.
  • neurodegenerative diseases such as Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis or other conditions in which neuronal cell death occurs, such as stroke or head trauma.
  • Coyle & Puttfarcken Science. 262. 689-695 (1993); Upton and Rosenberg, New En ⁇ l. J. of Medicine. 330. 613-622 (1993); Choi, Neuron. 1 , 623-634 (1988).
  • pharmacological agents that increase the activity of GlyT1 will result in decreased glycine- activation of NMDA receptors, which activity can be used to treat these and related disease states.
  • drugs that directly block the glycine site of the NMDA receptors can be used to treat these and related disease states.
  • Glycine transport inhibitors are already known in the art, for example as disclosed in published International Applications WO97/45423 (Trophix Pharmaceuticals, Inc.), and WO97/45115 (Trophix Pharmaceuticals Inc.).
  • the classes of compounds disclosed in these applications inhibit glycine transport via the GlyTI or GlyT2 transporters.
  • glycine transport inhibitors include published International Applications WO99/45011 (Janssen Pharmaceutica N.V.), WO00/07978 (Akzo Nobel N.V.) and WO01/87855 (Yamanouchi Pharmaceutical Co. Ltd.).
  • Published International Applications WO01/32602 and WO01/81308 disclose classes of compounds which inhibit glycine transport (or reuptake) via the GlyTI transporter.
  • Published International Applications WO01/36423 (Akzo Nobel N.V.) and WO03/55478 (SmithKline Beecham pic) disclose compounds that inhibit glycine transport by the human GlyTI transporter .
  • GlyTI transporters include those that inhibit GlyTI transporters selectively over GlyT2 transporters.
  • Such compounds would thus be suitable for the treatment of certain neurological and neuropsychiatric disorders, including psychoses such as schizophrenia, dementia and other forms of impaired cognition such as attention deficit disorders and organic brain syndromes.
  • neuropsychiatric disorders include drug-induced (phencyclidine, ketamine and other dissociative anaesthetics, amphetamine and other psychostimulants and cocaine) psychosis, psychosis associated with affective disorders, brief reactive psychosis, schizoaffective psychosis, and psychosis NOS, "schizophrenia- spectrum” disorders such as schizoid or schizotypal personality disorders, or illness associated with psychosis (such as major depression, manic depressive (bipolar) disorder, Alzheimer's disease and post-traumatic stress syndrome), and NMDA receptor- related disorders such as autism, depression, benign forgetfulness, childhood learning disorders and closed head injury.
  • drug-induced phencyclidine, ketamine and other dissociative anaesthetics, amphetamine and other psychostimulants and cocaine
  • psychosis psychosis associated with affective disorders
  • brief reactive psychosis schizoaffective psychosis
  • psychosis NOS "schizophrenia- spectrum” disorders such as schizo
  • R 1 and R 2 are independently:
  • Q is an optionally substituted 4-, 5-, 6- or 7-membered saturated ring, wherein one or more of the carbon atoms of the saturated ring is optionally replaced by a heteroatom independently selected from N, O and S, and R 15 , R 16 , R 17 and R 18 are independently hydrogen or d-Ce alkyl; R 3 is
  • Y is C-
  • R 4 and R 5 are both hydrogen, or one of R 4 and R 5 is hydrogen and the other is: (a) -SO2R 19 wherein R 19 is a 5- to 7- membered optionally substituted monocyclic aromatic ring system or a 6- to 11- membered optionally substituted bicyclic aromatic ring system; or (b) -XR 20 wherein X is -CO(CH2)r- (wherein r is 0, 1 , 2, 3 or 4) or -CONH- wherein R 20 is hydrogen, C ⁇ -C 6 alkyl or a 5- to 7- membered optionally substituted monocyclic aromatic ring system or a 6- to 11- membered optionally substituted bicyclic aromatic ring system;
  • R 6 is independently selected from hydrogen, C ⁇ -C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 - Cecycloalkyld-C ⁇ alkyl, aryl and arylC- ⁇ -C 4 alkyl; and
  • R 7 , R 8 , R 9 and R 10 are independently selected from hydrogen, C.
  • d.Ce alkyl refers to a straight or branched chain hydrocarbon which contains at least 1 , and at most 6, carbon atoms.
  • C C 6 alkyl groups useful in the present invention include, but are not limited to, methyl, ethyl, n-propyl, i- propyl, n-butyl, i-butyl, t-butyl, n-pentyl and n-hexyl.
  • C 4 alkyl refers to a straight or branched chain hydrocarbon which contains at least 1 , and at most 4, carbon atoms.
  • C C 4 alkyl groups useful in the present invention include, but are not limited to, methyl, ethyl, n-propyl, i- propyl, n-butyl, i-propyl and t-butyl.
  • C 3- C 6 cycloalkyl refers to a non-aromatic cyclic hydrocarbon ring having from three to six carbon atoms. Examples of “C 3 -C 6 cycloalkyl” groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • C 3 -C 6 cycloalkylC 1 -C 4 alkyl refers to a C 3- C 6 cycloalkyl group, as hereinbefore defined, attached through a C- ⁇ -C 4 alkylene linker, wherein C- ⁇ -C 4 alkylene is as defined herein.
  • Examples of "C 3 -C 6 cycloalkylC 1 -C 4 alkyl” include, but are not limited to, cyclohexylmethyl.
  • aryl refers to a 5- to 7-membered aromatic or heteroaromatic ring system wherein the heteroatomic ring contains at least one heteroatom selected from nitrogen, oxygen and sulphur.
  • aryl groups include phenyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, oxadiazolyl, isothiazolyl, thiazolyl, furyl, thienyl, pyridyl, thiazinyl, pyridazinyl, pyrimidinyl, pyrazinyl and azepinyl.
  • arylC C 4 alkyl refers to an aryl group, as hereinbefore defined, attached through a C C 4 alkylene linker, wherein C C 4 alkylene is as defined herein.
  • Examples of “arylC C 4 alkyl” include, but are not limited to, benzyl, phenethyl, pyridylmethyl and phenylpropyl.
  • C ⁇ .C 2 alkylene As used herein, the terms “C ⁇ .C 2 alkylene”, “C-i.Cs alkylene” and “C ⁇ ,C 4 alkylene” refer to a straight or branched chain divalent hydrocarbon radical, which contains at least 1 , and at most 2, 3 or 4, carbon atoms respectively.
  • Examples of “d-C 2 alkylene”, “C ⁇ _C 3 alkylene” and “d.d alkylene” groups useful in the present invention include methylene, ethylene, n- propylene and n-butylene.
  • C 2 alkenylene refers to a divalent hydrocarbon radical with a double bond, which contains 2 carbon atoms.
  • C 2 alkynylene refers to a divalent hydrocarbon radical with a triple bond, which contains 2 carbon atoms.
  • hal and halo are abbreviations for "halogen” and refers to fluorine, chlorine, bromine, or iodine.
  • 5- to 7- membered monocyclic aromatic ring system refers to a monocyclic aromatic ring system consisting of 5, 6 or 7 carbon atoms, wherein one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from nitrogen, oxygen and sulfur.
  • Examples of such groups include: phenyl, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyrazolyl, isothiazolyl, thiazolyl, isoxazolyl, furazanyl, oxazolyl, furyl, thienyl, pyridyl, pyridazinyl, pyrimidinyl, oxadiazolyl, triazolyl, thiadiazolyl, pyrazinyl, triazinyl, azepinyl and pyranyl.
  • 6- to 11- membered bicyclic aromatic ring system refers to a bicyclic aromatic ring system consisting of 6, 7, 8, 9, 10 or 11 carbon atoms, wherein one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from nitrogen, oxygen and sulfur.
  • the term includes bicyclic aromatic ring systems wherein both rings are aromatic, as well as bicyclic aromatic ring systems wherein one of the rings is partially or fully saturated.
  • bicyclic aromatic ring systems in which both rings are aromatic include: naphthyl, indenyl, indolyl, isoindolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzothienyl, benzofuranyl, naphthridinyl, quinolyl, quinoxalinyl, quinazolinyl and isoquinolyl.
  • bicyclic aryl groups in which one of the rings is partially or fully saturated includes dihydrobenzofuranyl, indanyl, tetrahydronaphthyl, indolinyl, isoindolinyl, tetrahydroisoquinolinyl, tetrahydroquinolyl, benzoxazinyl and benzoazepinyl.
  • All of these ring systems may be attached to the rest of the molecule via any available atom on the ring system, such as carbon or nitrogen.
  • salt refers to any salt of a compound according to the present invention prepared from an inorganic or organic acid or base, quaternary ammonium salts and internally formed salts.
  • Physiologically acceptable salts are particularly suitable for medical applications because of their greater aqueous solubility relative to the parent compounds. Such salts must clearly have a physiologically acceptable anion or cation.
  • physiologically acceptable salts of the compounds of the present invention include acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, hydroiodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and with organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, formic, propionic, glycolic, gluconic, maleic, succinic, camphorsulfuric, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, stearic, sulfinilic, alginic, galacturonic and arylsulfonic, for example benzenesul, in
  • solvate refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or formula (la), or a salt or physiologically functional derivative thereof) and a solvent.
  • solvents for the purpose of the invention may not interfere with the biological activity of the solute.
  • suitable solvents include, but are not limited to, water, methanol, ethanol and acetic acid.
  • the solvent used is a pharmaceutically acceptable solvent.
  • suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid. Most preferably the solvent used is water.
  • physiologically functional derivative refers to any pharmaceutically acceptable derivative of a compound of the present invention, for example, an ester or an amide, which upon administration to a mammal is capable of providing (directly or indirectly) a compound of the present invention or an active metabolite thereof.
  • physiologically functional derivatives are clear to those skilled in the art, without undue experimentation, and with reference to the teaching of Burger's Medicinal Chemistry And Drug Discovery, 5 th Edition, Vol 1 : Principles and Practice, which is incorporated herein by reference to the extent that it teaches physiologically functional derivatives.
  • Suitable substituents for groups in formula (I) which are optionally substituted include one or more groups selected from: halogen, hydroxy, oxo, cyano, nitro, C-j. alkyl, C-] ⁇ alkoxy, haloci-4alkyl.
  • substituents may be different or the same. If substituent(s) is/are present, preferably the number of substituent(s) is 1 , 2, 3 or 4.
  • substituent(s) is/are present, preferably the number of substituent(s) is 1 , 2, 3 or 4.
  • Certain of the compounds described herein may exist in stereoisomeric forms (i.e. they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism). The individual stereoisomers (enantiomers and diastereoisomers) and mixtures of these are included within the scope of the present invention.
  • compounds of formulae (I) and (la) may exist in tautomeric forms other than that shown in the formulae and these are also included within the scope of the present invention.
  • optically pure enantiomer means that the compound contains greater than about 90 % of the desired isomer by weight, preferably greater than about 95 % of the desired isomer by weight, and most preferably greater than about 99 % of the desired isomer by weight, said weight percent based upon the total weight of the isomer(s) of the compound.
  • the compound of formula (I) as hereinbefore described has the following stereochemical configuration:
  • R 1 and R 2 are independently selected from optionally substituted d-C 6 alkyl, preferably C 3 -C 6 alkyl such as isopropyl.
  • the optional substituents for the d-C 6 alkyl may be one, two or three groups selected from: halogen, C-
  • R 1 and R 2 together with the nitrogen atom to which they are attached are linked to form a 4-, 5-, 6- or 7-membered heterocyclic ring, wherein the sole heteroatom is the nitrogen atom to which R 1 and R 2 are attached, said ring being optionally substituted by one, two or three groups selected from: halogen, Chalky!, C-j. 4alkoxy, haloci-4alky[, haloC ⁇ alkoxy, C ⁇ alkylsulfonamidoC- ⁇ alkyl, C-
  • R 1 and R 2 together with the nitrogen atom to which they are attached are linked to form a 5- or 6-membered ring, wherein one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from N, O and S, said ring being optionally substituted by one, two or three groups selected from: halogen,
  • R 21 R 22 forms part of a C3_ ⁇ azacyloalkane or C3_6(2-oxo)azacycloalkane ring and r represents zero or an integer from 1 to 4), said ring being further optionally fused to a C 5 -
  • R 1 and R 2 together with the nitrogen atom to which they are attached are linked to form a 5- or 6-membered heterocyclic ring, wherein the sole heteroatom is the nitrogen atom to which R 1 and R 2 are attached, said ring being optionally substituted by one, two or three groups selected from: halogen, C- ⁇ _galkyl, C-
  • the 4-, 5-, 6- or 7-membered saturated ring formed by R 1 and R 2 together with the nitrogen atom to which they are linked is selected from the group comprising: azetidine, azepine, pyrrolidine, imidazolidine, piperidine, morpholine, thiomorpholine, piperazine, all of which being optionally substituted by one, two or three groups selected from: halogen, C ⁇ .galkyl, C-j ⁇ alkoxy, haloci-4.alkyl, haloC-] ⁇ alkoxy, C ⁇ _
  • R 1 and R 2 together with the nitrogen atom to which they are attached are linked to form a pyrrolidinyl ring, said ring being optionally substituted by one or more groups independently selected from optionally substituted C 1 -C 4 alkyl, preferably methyl, ethyl or isopropyl.
  • the pyrrolidinyl ring formed by R 1 and R 2 together with the nitrogen atom to which they are attached is substituted by one or more d-C 4 alkyl groups, preferably methyl, ethyl or isopropyl groups, preferably at the 2- and/or 5- positions, more preferably at the 2-position.
  • R 1 and R 2 together with the nitrogen atom to which they are attached are linked to form a piperidinyl ring, said ring being optionally substituted by one or more groups independently selected from optionally substituted C 1 -C 4 alkyl , preferably methyl or ethyl.
  • the piperidinyl ring formed by R 1 and R 2 together with the nitrogen atom to which they are attached is substituted by one or more methyl or ethyl groups, preferably at the 2- and 6-positions. More preferably, the piperidinyl ring formed by R 1 and R 2 together with the nitrogen atom to which they are attached is substituted by two methyl groups, preferably at the 2- and 6- positions.
  • q is 0.
  • Z is substituted by 1 , 2 or 3 groups independently selected from: - hal, -R 23 , -OR 24 , -C(O)OR 25 , -CN, -NO 2 , -NR 26 R 27 , -C(O)NR 28 R 29 , -NR 30 C(O)R 31 , - C(O)R 32 , -C(NR 33 )NR 34 R 35 , -C(NOR 36 )R 37 , or C ⁇
  • Z is a 5- to 7-membered optionally substituted monocyclic aromatic ring system as hereinbefore described.
  • Z is a 5- or 6-membered optionally substituted monocyclic ring system as hereinbefore described.
  • Z is phenyl optionally substituted as hereinbefore described, preferably by one or more groups independently selected from -hal, -R 10 , -CF3, -C-
  • Z is a 6- to 11 -membered optionally substituted bicyclic aromatic ring system as hereinbefore described.
  • Z is a 8- to 10- membered optionally substituted bicyclic aromatic ring system as hereinbefore described.
  • Z is selected from the group comprising: naphthyl, naphthyridinyl, quinolinyl, isoquinolyl, benzothienyl, chromanyl, chromenyl, imidazoleisothiazolyl, benzothiadiazolyl, benzofuryl, all of which being optionally substituted as hereinbefore described.
  • Z is quinolinyl (preferably 5-quinolinyl), optionally substituted as hereinbefore described, preferably by one or more groups independently selected from -hal, -R 23 , -OR 24 , - COOR 25 , -CF3, -Ci-C ⁇ alkylsulphonyl, -CN, -NO 2 , and -NR 26 R 27 , wherein hal, R 23 , R 24 , R 25 , R 26 and R 27 are as hereinbefore defined, preferably hal, d-C 6 alkyl, Ci-Ce alkoxy, CF3, -CN and C 3 -C 6 cycloalkyl.
  • Z is 5-quinolinyl optionally substituted by one or more groups independently selected from -hal, d-C 6 alkyl, d-C 6 alkoxy, - CF3, -CN and C 3 -C 6 cycloalkyl.
  • R 3 is phenyl or 5-quinolinyl.
  • one of R 4 and R 5 is hydrogen and the other is a group -COCH2R 38 , - COR 38 or -CONHR 38 wherein R 38 is a 5- to 7- membered monocylic aromatic ring system or a 6- to 11- membered bicyclic aromatic ring system, said ring system being optionally substituted by one or two groups independently selected from hal, CF3, d-C 6 alkyl, d- C 6 alkoxy,-CN, d-Cealkylamido, d-C 6 alkanoyl and d-C 6 alkylsulphonyl.
  • R 6 is selected from hydrogen, d-C 6 alkyl, aryl and benzyl, wherein the d ⁇ C 6 alkyl, aryl and benzyl are optionally substituted by one or more groups independently selected from hal, d-C 6 alkyl, hydroxy and d-C 6 alkoxy.
  • R 6 is hydrogen.
  • R 7 , R 8 , R 9 and R 10 are independently selected from hydrogen and Ci- Ce alkyl, preferably hydrogen.
  • R 39 and R 40 are independently selected from C 3 -C 6 alkyl, or
  • R 39 and R 40 together with the nitrogen atom to which they are attached, are linked to form a 5-, 6-, or 7- membered heterocyclic ring, wherein the sole heteroatom is the nitrogen atom to which R 39 and R 40 are attached, said heterocyclic ring being optionally substituted by one or more groups independently selected from C 1 -C 4 alkyl and C 3 -C 6 cycloalkyl, and said heterocyclic ring being further optionally fused to a C 6 alicyclic or aromatic ring, and said heterocyclic ring being further optionally bridged by a methylene group;
  • R 42 and R 43 is hydrogen and the other is a group -X 1 R 49 , wherein X-, is CONH- or - CO(CH2)b- wherein b is 0, 1 or 2, and R 49 is a 5- to 6-membered monocylic aromatic ring system or a 6- to 10- membered bicyclic aromatic ring system, said ring system being optionally substituted by one, two or three groups independently selected from -hal, -R 50 , -OR 51 , -C(O)OR 52 , -CN, -NO 2 , -NR 53 R 54 , -C(O)NR 55 R 56 , -NR 57 C(O)R 58 , -C(O)R 59 , - C(NR 60 )NR 6 R 62 , -C(NOR 63 )R 64 , or C-
  • X- is CONH- or - CO(CH2)b- wherein b is 0, 1 or 2
  • R 49 is a
  • R 50 is d-C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkylC 1 -C 4 alkyl, aryl, aryloxy or arylC 1 -C 4 alkyl, all of which being optionally substituted by one or more groups independently selected from hal, C
  • the C 2 alkenylene group may be in the cis or trans configuration, preferably the trans configuration.
  • a is 0.
  • the compound of formula (la) as hereinbefore described has the following stereochemical configuration:
  • Examples of preferred compounds of the invention include Examples 1 to 42 shown below, as well as salts, solvates and physiologically functional derivatives thereof:
  • the compounds of formulae (I) and (la) have the ability to crystallise in more than one form, a characteristic, which is known as polymorphism, and it is understood that such polymorphic forms (“polymorphs”) are within the scope of formulae (I) and (la).
  • Polymorphism generally can occur as a response to changes in temperature or pressure or both and can also result from variations in the crystallisation process. Polymorphs can be distinguished by various physical characteristics known in the art such as x-ray diffraction patterns, solubility, and melting point.
  • the compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working
  • a compound When a compound is desired as a single enantiomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be effected by any suitable method known in the art. See, for example, Stereochemistry of Organic Compounds by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-lnterscience, 1994).
  • the compounds of formula (A) may be prepared using methodology similar to that described by Gutcait A. et. al., Tetrahedron Asymmetry, 1996, 7(6), 1641-1648.
  • Compounds of formula (A) may be converted to compounds of formula (I) above by displacement of the hydroxyl with azide, as shown above.
  • the reduction of the azide may be carried out using all methods known to those skilled in the art, for example, hydrogenation in the presence of catalyst such as palladium on carbon, Pd(OH) 2 and those known in the art, see for example March, Advanced Organic Chemistry, 4 th edition, Wiley Interscience.
  • the reduction of the azide is preferably carried out by hydrogenation in the presence of a catalyst such as palladium on carbon.
  • Schemes 1 and 2 can be adapted to prepare compounds wherein R 6 , R 7 , R 8 , R 9 and R 10 are other than hydrogen.
  • R 3 is as hereinbefore defined and L is a suitable leaving group, such as, for example, a halogen, preferably chlorine; or
  • the present invention provides a compound of formula (I) or formula (1a) as hereinbefore described and salts, solvates and physiologically functional derivatives thereof, for use in therapy.
  • the present invention provides a compound of formula (I) or formula (1a) as hereinbefore described and salts, solvates and physiologically functional derivatives thereof, for use in treating a disorder mediated by GlyTI .
  • a method of treating a mammal including a human, suffering from or susceptible to a disorder mediated by GlyTI , which comprises administering an effective amount of a GlyTI inhibiting compound of formula (I) or (la) as hereinbefore defined or a salt, solvate or a physiologically functional derivative thereof.
  • the terms “therapy” and “treatment” refer to alleviation and/or cure of established symptoms as well as prophylaxis.
  • an effective amount means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
  • the present invention also provides the use of a compound of formula (I) or formula (la) as hereinbefore defined or a salt, solvate or a physiologically functional derivative thereof in the preparation of a medicament for the treatment of a disorder mediated by GlyTI .
  • a disorder mediated by GlyTI refers to a disorder that may be treated by the administration of a medicament that alters the activity of the GlyTI transporter.
  • the action of GlyTI transporters affects the local concentration of glycine around NMDA receptors.
  • any change to that local concentration can affect NMDA-mediated neurotransmission.
  • changes in NMDA-mediated neurotransmission have been implicated in certain neuropsychiatric disorders such as dementia, depression and psychoses, for example schizophrenia, and learning and memory disorders, for example attention deficit disorders and autism.
  • alterations in the activity of the GlyTI transporter are expected to influence such disorders.
  • the disorders mediated by GlyTI referred to herein include neurological and neuropsychiatric disorders, including psychoses such as schizophrenia, dementia and other forms of impaired cognition such as attention deficit disorders and organic brain syndromes.
  • Other neuropsychiatric disorders include drug-induced (phencyclidine, ketamine and other dissociative anesthetics, amphetamine and other psychostimulants and cocaine) psychosis, psychosis associated with affective disorders, brief reactive psychosis, schizoaffective psychosis, and psychosis NOS, "schizophrenia-spectrum" disorders such as schizoid or schizotypal personality disorders, or illness associated with psychosis (such as major depression, manic depressive (bipolar) disorder, Alzheimer's disease and post-traumatic stress syndrome), and NMDA receptor-related disorders such as autism, depression, benign forgetfulness, childhood learning disorders and closed head injury.
  • NMDA receptor-related disorders such as autism, depression, benign forgetfulness, childhood learning disorders and closed head injury.
  • the disorders mediated by GlyTI to be treated by the use or method as hereinbefore described are psychoses, including schizophrenia, dementia and attention deficit disorders, particularly schizophrenia.
  • Compounds for use according to the invention may be administered as the raw material but the active ingredients are preferably provided in the form of pharmaceutical compositions.
  • a pharmaceutical composition comprising as active ingredient the compound of formula (I) or formula (la) as hereinbefore described, or a salt, solvate or a physiologically functional derivative thereof, and at least one pharmaceutically acceptable carrier, diluent or excipient.
  • compositions may be used in the treatment of clinical conditions for which a GlyTI inhibitor is indicated such as, for example, schizophrenia.
  • the carrier must be pharmaceutically acceptable to the recipient and must be compatible with, i.e. not have a deleterious effect upon, the other ingredients in the composition.
  • the carrier may be a solid or a liquid and is preferably formulated with at least one compound of formula (I) or (la) as hereinbefore described as a unit dose formulation. If desired, other physiologically active ingredients may also be incorporated in the pharmaceutical compositions of the invention.
  • DSM-IV American Psychiatric Association
  • the compounds of formula (I) are of use in the treatment of schizophrenia including the subtypes Paranoid Type (295.30), Disorganised Type (295.10), Catatonic Type (295.20), Undifferentiated Type (295.90) and Residual Type (295.60); Schizophreniform Disorder (295.40); Schizoaffective Disorder (295.70) including the subtypes Bipolar Type and Depressive Type; Delusional Disorder (297.1) including the subtypes Erotomanic Type, Grandiose Type, Jealous Type, Persecutory Type, Somatic Type, Mixed Type and Unspecified Type; Brief Psychotic Disorder (298.8); Shared Psychotic Disorder (297.3); Psychotic Disorder Due to a General Medical Condition including the subtypes With Delusions and With Hallucinations; Substance-Induced Psychotic Disorder including the subtypes With Delusions (293.81) and With Hallucinations (293.82); and Psychotic Disorder Not Otherwise Specified (298.9).
  • the compounds of formula (I) are also of use in the treatment of mood disorders including Major Depressive Episode, Manic Episode, Mixed Episode and Hypomanic Episode; Depressive Disorders including Major Depressive Disorder, Dysthymic Disorder (300.4), Depressive Disorder Not Otherwise Specified (311); Bipolar Disorders including Bipolar I Disorder, Bipolar II Disorder (Recurrent Major Depressive Episodes with Hypomanic Episodes) (296.89), Cyclothymic Disorder (301.13) and Bipolar Disorder Not Otherwise Specified (296.80); Other Mood Disorders including Mood Disorder Due to a General Medical Condition (293.83) which includes the subtypes With Depressive Features, With Major Depressive-like Episode, With Manic Features and With Mixed Features), Substance-Induced Mood Disorder (including the subtypes With Depressive Features, With Manic Features and With Mixed Features) and Mood Disorder Not Otherwise Specified (296.90).
  • the compounds of formula (I) are also of use in the treatment of anxiety disorders including Panic Attack, Agoraphobia, Panic Disorder, Agoraphobia Without History of Panic Disorder (300.22), Specific Phobia (300.29) including the subtypes Animal Type, Natural Environment Type, Blood-lnjection-lnjury Type, Situational Type and Other Type), Social Phobia (300.23), Obsessive-Compulsive Disorder (300.3), Posttraumatic Stress Disorder (309.81), Acute Stress Disorder (308.3), Generalized Anxiety Disorder (300.02), Anxiety Disorder Due to a General Medical Condition (293.84), Substance-Induced Anxiety Disorder and Anxiety Disorder Not Otherwise Specified (300.00).
  • the compounds of formula (I) are also of use in the treatment of substance-related disorders including Substance Use Disorders such as Substance Dependence and Substance Abuse; Substance-Induced Disorders such as Substance Intoxication, Substance Withdrawal, Substance-Induced Delirium, Substance-Induced Persisting Dementia, Substance-Induced Persisting Amnestic Disorder, Substance-Induced Psychotic Disorder, Substance-Induced Mood Disorder, Substance-Induced Anxiety Disorder, Substance-Induced sexual Dysfunction, Substance-Induced Sleep Disorder and Hallucinogen Persisting Perception Disorder (Flashbacks); Alcohol-Related Disorders such as Alcohol Dependence (303.90), Alcohol Abuse (305.00), Alcohol Intoxication (303.00), Alcohol Withdrawal (291.81), Alcohol Intoxication Delirium, Alcohol Withdrawal Delirium, Alcohol-Induced Persisting Dementia, Alcohol-Induced Persisting Amnestic Disorder, Alcohol-
  • the compounds of formula (I) are also of use in the treatment of sleep disorders including primary sleep disorders such as Dyssomnias such as Primary Insomnia (307.42), Primary Hypersomnia (307.44), Narcolepsy (347), Breathing-Related Sleep Disorders (780.59), Circadian Rhythm Sleep Disorder (307.45) and Dyssomnia Not Otherwise Specified (307.47); primary sleep disorders such as Parasomnias such as Nightmare Disorder (307.47), Sleep Terror Disorder (307.46), Sleepwalking Disorder (307.46) and Parasomnia Not Otherwise Specified (307.47); Sleep Disorders Related to Another Mental Disorder such as Insomnia Related to Another Mental Disorder (307.42) and Hypersomnia Related to Another Mental Disorder (307.44); Sleep Disorder Due to a General Medical Condition; and Substance-Induced Sleep Disorder including the subtypes Insomnia Type, Hypersomnia Type, Parasomnia Type and Mixed Type.
  • the compounds of formula (I) are also of use in the treatment of eating disorders such as Anorexia Nervosa (307.1 ) including the subtypes Restricting Type and Binge- Eating/Purging Type; Bulimia Nervosa (307.51 ) including the subtypes Purging Type and Nonpurging Type; Obesity; Compulsive Eating Disorder; and Eating Disorder Not Otherwise Specified (307.50).
  • eating disorders such as Anorexia Nervosa (307.1 ) including the subtypes Restricting Type and Binge- Eating/Purging Type; Bulimia Nervosa (307.51 ) including the subtypes Purging Type and Nonpurging Type; Obesity; Compulsive Eating Disorder; and Eating Disorder Not Otherwise Specified (307.50).
  • the compounds of formula (I) are also of use in the treatment of Autistic Disorder (299.00); Attention-Deficit /Hyperactivity Disorder including the subtypes Attention-Deficit /Hyperactivity Disorder Combined Type (314.01), Attention-Deficit /Hyperactivity Disorder Predominantly Inattentive Type (314.00), Attention-Deficit /Hyperactivity Disorder Hyperactive-Impulse Type (314.01 ) and Attention-Deficit /Hyperactivity Disorder Not Otherwise Specified (314.9); Hyperkinetic Disorder; Disruptive Behaviour Disorders such as Conduct Disorder including the subtypes childhood-onset type (321.81), Adolescent- Onset Type (312.82) and Unspecified Onset (312.89), Oppositional Defiant Disorder (313.81) and Disruptive Behaviour Disorder Not Otherwise Specified; and Tic Disorders such as Tourette's Disorder (307.23).
  • Attention-Deficit /Hyperactivity Disorder including the subtypes Attention-Defici
  • the compounds of formula (I) are also of use in the treatment of Personality Disorders including the subtypes Paranoid Personality Disorder (301.0), Schizoid Personality Disorder (301.20), Schizotypal Personality Disorder (301 ,22), Antisocial Personality Disorder (301.7), Borderline Personality Disorder (301 ,83), Histrionic Personality Disorder (301.50), Narcissistic Personality Disorder (301,81), Avoidant Personality Disorder (301.82), Dependent Personality Disorder. (301.6), Obsessive-Compulsive Personality Disorder (301.4) and Personality Disorder Not Otherwise Specified (301.9).
  • Paranoid Personality Disorder (301.0
  • Schizoid Personality Disorder 301.20
  • Schizotypal Personality Disorder 301 ,22
  • Antisocial Personality Disorder (301.7
  • Borderline Personality Disorder 301 ,83
  • Histrionic Personality Disorder 301.50
  • Narcissistic Personality Disorder 301,81
  • Avoidant Personality Disorder (301.82)
  • Dependent Personality Disorder (301.6
  • the compounds of Formula (I) are also of use in the enhancement of cognition including the treatment of cognition impairment in other diseases such as schizophrenia, bipolar disorder, depression, other psychiatric disorders and psychotic conditions associated with cognitive impairment.
  • cognitive impairment includes for example the treatment of impairment of cognitive functions including attention, orientation, learning disorders, memory (i.e.
  • Alzheimer's disease Huntington's disease, Pick disease, Aids-related dementia or other dementia states
  • Multiinfarct dementia alcoholic dementia, hypotiroidism-related dementia, and dementia associated to other degenerative disorders such as cerebellar atrophy and amyotropic lateral sclerosis
  • other acute or sub-acute conditions that may cause cognitive decline such as delirium or depression (pseudodementia states) trauma, head trauma, age related cognitive decline, stroke, neurodegeneration, drug-induced states, neurotoxic agents, mild cognitive impairment, age related cognitive impairment, autism related cognitive impairment, Down's syndrome, cognitive deficit related to psychosis, and post-electroconvulsive treatment related cognitive disorders
  • dyskinetic disorders such as Parkinson's disease, neuroleptic-induced parkinsonism, and tardive dyskinesias.
  • the compounds of formula (I) are also of use in the treatment of sexual dysfunctions including Sexual Desire Disorders such as Hypoactive Sexual Desire Disorder (302.71), and Sexual Aversion Disorder (302.79); sexual arousal disorders such as Female sexual Arousal Disorder (302.72) and Male Erectile Disorder (302.72); orgasmic disorders such as Female Orgasmic Disorder (302.73), Male Orgasmic Disorder (302.74) and Premature Ejaculation (302.75); sexual pain disorder such as Dyspareunia (302.76) and Vaginismus (306.51); sexual Dysfunction Not Otherwise Specified (302.70); paraphilias such as Exhibitionism (302.4), Fetishism (302.81), Frotteurism (302.89), Pedophilia (302.2), sexual Masochism (302.83), Sexual Sadism (302.84), Transvestic Fetishism (302.3), - Voyeurism (302.82) and Paraphilia Not Otherwise Specified (302.9); gender identity disorders such as Gender Identity Disorder in Children (302.6) and Gender Identity Disorder
  • the invention also provides a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of schizophrenia, mood disorders, anxiety disorders, substance-related disorders, sleep disorders, eating disorders, autistic disorder, attention-deficit/hyperactivity disorder, disruptive behaviour disorder, tic disorders, personality disorders, cognition impairment in other diseases, sexual dysfunction, Parkinson's disease, dyskinetic disorders, depression, bipolar disorder, cognitive impairment, obesity, emesis, movement disorders, obsessive- compulsive disorders, amnesia, aggression, vertigo, dementia and circadian rhythm disorders.
  • the invention also provides a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of psychotic disorders, schizophrenia, Parkinson's disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders.
  • psychotic disorders schizophrenia, Parkinson's disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders.
  • a method of treating a mammal including a human, suffering from or susceptible to a disorder mediated by GlyTI , which comprises administering an effective amount of a compound of formula (I) as hereinbefore defined or a salt or solvate thereof.
  • the invention also provides a method of treating schizophrenia, mood disorders, anxiety disorders, substance-related disorders, sleep disorders, eating disorders, autistic disorder, attention-deficit/hyperactivity disorder, disruptive behaviour disorder, tic disorders, personality disorders, cognition impairment in other diseases, sexual dysfunction, Parkinson's disease, dyskinetic disorders, depression, bipolar disorder, cognitive impairment, obesity, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, vertigo, dementia and circadian rhythm disorders which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof.
  • the invention also provides a method of treating psychotic disorders, schizophrenia, Parkinson's disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof.
  • the disorder mediated by GlyTI to be treated by the use or method as hereinbefore described is a psychosis, including schizophrenia, dementia and attention deficit disorders, particularly schizophrenia.
  • the invention also provides the use of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of schizophrenia, mood disorders, anxiety disorders, substance-related disorders, sleep disorders, eating disorders, autistic disorder, attention- deficit/hyperactivity disorder, disruptive behaviour disorder, tic disorders, personality disorders, cognition impairment in other diseases, sexual dysfunction, Parkinson's disease, dyskinetic disorders, depression, bipolar disorder, cognitive impairment, obesity, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, vertigo, dementia and circadian rhythm disorders.
  • the invention also provides the use of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of psychotic disorders, schizophrenia, Parkinson's disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders.
  • psychotic disorders schizophrenia, Parkinson's disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders.
  • the term "effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
  • Compounds for use according to the invention may be administered as the raw material but the active ingredients are preferably provided in the form of pharmaceutical compositions.
  • a pharmaceutical composition comprising a compound of formula (I) as hereinbefore described or a salt or solvate thereof, and at least one pharmaceutically acceptable carrier, diluent or excipient.
  • These pharmaceutical compositions may be used in the treatment of clinical conditions for which a GlyTI inhibitor is indicated such as, for example, schizophrenia.
  • the carrier must be pharmaceutically acceptable to the recipient and must be compatible with, i.e. not have a deleterious effect upon, the other ingredients in the composition.
  • the carrier may be a solid or a liquid and is preferably formulated with at least one compound of formula (I) or a salt or solvate thereof as a unit dose formulation. If desired, other physiologically active ingredients may also be incorporated in the pharmaceutical compositions of the invention.
  • the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents such as 5HT3 antagonists, serotonin agonists, NK-1 antagonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants, dopaminergic antidepressants, H3 antagonists, 5HT1A antagonists, 5HT1B antagonists, 5HT1D antagonists, D1 agonists, M1 agonists and/or anticonvulsant agents, as well as atypical antipsychotic drugs and cognitive enhancers.
  • different antidepressant agents such as 5HT3 antagonists, serotonin agonists, NK-1 antagonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants, dopaminergic antidepressants, H3 antagonists, 5HT1A antagonists, 5
  • Suitable 5HT3 antagonists which may be used in combination of the compounds of the inventions include for example ondansetron, granisetron, metoclopramide.
  • Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.
  • Suitable SSRIs which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.
  • Suitable SNRIs which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.
  • Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptiline, chlomipramine and nortriptiline.
  • Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.
  • Suitable anticonvulsant agents which may be used in combination of the compounds of the invention include for example divalproex, carbamazepine and diazepam.
  • Suitable atypical antipsychotic drugs which which may be used in combination of the compounds of the invention include for example risperidone, olanzapine, ziprasidone, aripiprazole and clozapine. It will be appreciated that the compounds of the combination or composition may be administered simultaneously (either in the same or different pharmaceutical formulations), separately or sequentially.
  • the compounds of formula (I) and their pharmaceutically acceptable salts and solvates thereof are also suitable for combination with other typical and atypical antipsychotics to provide improved treatment of psychotic disorders.
  • Particular advantages associated with the combinations, uses and methods of treatment of compounds of formula (I) and their pharmaceutically acceptable salts and solvates thereof include equivalent or improved efficacy at doses of administration which are lower than those commonly used for the individual components. Improved treatments of positive symptoms and/or negative symptoms and/or cognitive symptoms of the psychotic disorder may also be observed.
  • the combinations, uses and methods of treatment of the invention may also provide advantages in treatment of patients who fail to respond adequately or who are resistant to treatment with certain neuroleptic agents.
  • adjunctive administration is meant the coterminous or overlapping administration of each of the components in the form of separate pharmaceutical compositions or devices.
  • This regime of therapeutic administration of two or more therapeutic agents is referred to generally by those skilled in the art and herein as adjunctive therapeutic administration; it is also known as add-on therapeutic administration.
  • Any and all treatment regimes in which a patient receives separate but coterminous or overlapping therapeutic administration of the compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one neuroleptic agent are within the scope of .the current invention.
  • a patient is typically stabilised on a therapeutic administration of one or more of the of the components for a period of time and then receives administration of another component.
  • the compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof is administered as adjunctive therapeutic treatment to patients who are receiving administration of at least one neuroleptic agent, but the scope of the invention also includes the adjunctive therapeutic administration of at least one neuroleptic agent to patients who are receiving administration of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • the combination therapies of the invention may also be administered simultaneously.
  • simultaneous administration is meant a treatment regime wherein the individual components are administered together, either in the form of a single pharmaceutical composition or device comprising or containing both components, or as separate compositions or devices, each comprising one of the components, administered simultaneously.
  • Such combinations of the separate individual components for simultaneous combination may be provided in the form of a kit-of-parts.
  • the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof to a patient receiving therapeutic administration of at least one neuroleptic agent.
  • the invention provides the use of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one neuroleptic agent.
  • the invention further provides compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one neuroleptic agent.
  • the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of at least one neuroleptic agent to a patient receiving therapeutic administration of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • the invention provides the use of at least one neuroleptic agent in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • the invention further provides at least one neuroleptic agent for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof in combination with at least one neuroleptic agent.
  • the invention further provides the use of a combination of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one neuroleptic agent in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a psychotic disorder.
  • the invention further provides the use of compounds of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for simultaneous therapeutic administration with at least one neuroleptic agent in the treatment of a psychotic disorder.
  • the invention further provides compounds of formula (I) or a pharmaceutically acceptable salt thereof for use for simultaneous therapeutic administration with at least one neuroleptic agent in the treatment of a psychotic disorder.
  • the invention further provides the use of at least one neuroleptic agent in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) or a pharmaceutically acceptable salt thereof in the treatment of a psychotic disorder.
  • the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of a pharmaceutical composition comprising compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one mood stabilising or antimanic agent, a pharmaceutical composition comprising compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one mood stabilising or antimanic agent, the use of a pharmaceutical composition comprising compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one mood stabilising or antimanic agent in the manufacture of a medicament for the treatment of a psychotic disorder, and a pharmaceutical composition comprising compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one mood stabilising or antimanic agent for use in the treatment of a psychotic disorder.
  • the invention provides a kit-of-parts for use in the treatment of a psychotic disorder comprising a first dosage form comprising compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and one or more further dosage forms each comprising a neuroleptic agent for simultaneous therapeutic administration.
  • psychotic disorder includes those disorders mentioned above, such as schizophrenia, mood disorders, anxiety disorders, substance-related disorders, sleep disorders, eating disorders, autistic disorder, attention- deficit/hyperactivity disorder, disruptive behaviour disorder, tic disorders, personality disorders, cognition impairment in other diseases, sexual dysfunction, dyskinetic disorders, depression, bipolar disorder, cognitive impairment and obsessive-compulsive disorders and all the various forms of the disorders as mentioned herein.- which are contemplated as part of the present invention.
  • neuroleptic/antipsychotic drugs examples include, but are not limited to: butyrophenones, such as haloperidol, pimozide, and droperidol; phenothiazines, such as chlorpromazine, thioridazine, mesoridazine, trifluoperazine, perphenazine, fluphenazine, thiflupromazine, prochlorperazine, and acetophenazine; thioxanthenes, such as thiothixene and chlorprothixene thienobenzodiazepines; dibenzodiazepines; benzisoxazoles; dibenzothiazepines imidazolidinones ; benzisothiazolyl-piperazines; triazine such as lamotrigine dibenzoxazepines, such as loxapine; dihydroindolones, such as molindone; aripiprazole
  • neuroleptic drugs that are preferred for use in the present invention are shown in Table 1.
  • clozapine available under the tradename CLOZARIL®, from Mylan, Zenith Goldline, UDL, Novartis
  • olanzapine available under the tradename ZYPREX®, from Lilly
  • ziprasidone available under the tradename GEODON®, from Pfizer
  • risperidone available under the tradename RISPERDAL®, from Janssen
  • quetiapine fumarate available under the tradename SEROQUEL®, from AstraZeneca
  • haloperidol available under the tradename HALDOL®, from Ortho-McNeil
  • chlorpromazine available under the tradename THORAZINE®, from SmithKline Beecham (GSK); fluphenazine (available under the tradename PROLIXIN®, from Apothecon, Copley, Schering, Teva, and American Pharmaceutical Partners, Pasadena); thioth
  • neuroleptic drugs include promazine (available under the tradename SPARINE®), triflurpromazine (available under the tradename VESPRIN®), chlorprothixene (available under the tradename TARACTAN®), droperidol (available under the tradename INAPSINE®), acetophenazine (available under the tradename TINDAL®;), prochlorperazine (available under the tradename COMPAZINE®), methotrimeprazine (available under the tradename NOZINAN®), pipotiazine (available under the tradename PIPOTRIL®), ziprasidone, and hoperidone.
  • promazine available under the tradename SPARINE®
  • triflurpromazine available under the tradename VESPRIN®
  • chlorprothixene available under the tradename TARACTAN®
  • droperidol available under the tradename INAPSINE®
  • acetophenazine available under the tradename TINDAL®
  • prochlorperazine available under the tradename COMP
  • Particularly preferred neuroleptic agents for use in the invention are olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant.
  • Possible formulations include those suitable for oral, sub-lingual, buccal, parenteral (for example, subcutaneous, intramuscular, or intravenous), rectal, topical and intranasal administration and in forms suitable for administration by inhalation or insufflation (either through the mouth or nose).
  • parenteral for example, subcutaneous, intramuscular, or intravenous
  • rectal topical and intranasal administration and in forms suitable for administration by inhalation or insufflation (either through the mouth or nose).
  • inhalation or insufflation either through the mouth or nose.
  • Formulations suitable for oral administration may be provided as discrete units, such as tablets, capsules, cachets, or lozenges, each containing a predetermined amount of the active compound; as powders or granules; as solutions or suspensions in aqueous or non-aqueous liquids; or as oil-in-water or water-in-oil emulsions.
  • Formulations suitable for sublingual or buccal administration include lozenges comprising the active compound and, typically, a flavoured base, such as sugar and acacia or tragacanth and pastilles comprising the active compound in an inert base, such as gelatin and glycerin or sucrose and acacia.
  • Formulations suitable for parenteral administration typically comprise sterile aqueous solutions containing a predetermined concentration of the active compound; the solution is preferably isotonic with the blood of the intended recipient. Although such solutions are preferably administered intraveneously, they may also be administered by subcutaneous or intramuscular injection.
  • Formulations suitable for rectal administration are preferably provided as unit-dose suppositories comprising the active ingredient and one or more solid carriers forming the suppository base, for example, cocoa butter.
  • Formulations suitable for topical or intranasal application include ointments, creams, lotions, pastes, gels, sprays, aerosols and oils.
  • Suitable carriers for such formulations include petroleum jelly, lanolin, polyethylene glycols, alcohols, and combinations thereof.
  • the formulations of the invention may be prepared by any suitable method, typically by uniformly and intimately admixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions and then, if necessary, shaping the resulting mixture into the desired shape.
  • a tablet may be prepared by compressing an intimate mixture comprising a powder or granules of the active ingredient and one or more optional ingredients, such as a binder, lubricant, inert diluent, or surface active dispersing agent, or by moulding an intimate mixture of powdered active ingredient and inert liquid diluent.
  • one or more optional ingredients such as a binder, lubricant, inert diluent, or surface active dispersing agent, or by moulding an intimate mixture of powdered active ingredient and inert liquid diluent.
  • Aqueous solutions for parenteral administration are typically prepared by dissolving the active compound in sufficient water to give the desired concentration and then rendering the resulting solution sterile and isotonic.
  • the compound may be administered in single or divided doses and may be administered one or more times, for example 1 to 4 times per day.
  • a proposed dose of the active ingredient for use according to the invention for oral, sub- lingual, parenteral, buccal, rectal, intranasal or topical administration to a human (of approximately 70 kg bodyweight) for the treatment of neurological and neuropsychiatric disorders mediated by a GlyTI inhibitor, including schizophrenia, may be about 1 to about 1000 mg, preferably about 5 to about 500 mg, more preferably about 10 to about 100 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
  • M molar
  • mM millimolar
  • i. v. intravenous
  • Hz Hertz
  • T r retention time
  • RP reverse phase
  • TEA triethylamine
  • TFA trifluoroacetic acid
  • TFAA trifluoroacetic anhydride
  • THF tetrahydrofuran
  • DCE dichloroethane
  • DMF N./V-dimethylformamide
  • DMPU ⁇ /, ⁇ /'-dimethyIpropyleneurea
  • GDI 1,1-carbonyldiimidazole
  • IBCF isobutyl chloroformate
  • HOAc acetic acid
  • HOSu ⁇ /-hydroxysuccinimide
  • HOBT 1-hydroxybenzotriazole
  • mCPBA metal-chloroperbenzoic acid
  • EDC ethylcarbodiimide hydrochloride
  • BOC ife/ -butyloxycarbonyl
  • FMOC 9-fluorenylmethoxycarbonyl
  • DCC (dicyclohexylcarbodiimide); CBZ (benzyloxycarbonyl);
  • TIPS triisopropylsilyl
  • TBS f-butyldimethylsilyl
  • Me methyl
  • HPLC high pressure liquid chromatography
  • MS mass spectra
  • MS and liquid chromatography MS were recorded on a Micromass MS2 Platform LC spectrometer. All mass spectra were taken under electrospray ionisation (ESI), chemical ionisation (Cl), electron impact (El) or by fast atom bombardment (FAB) methods. All reactions were monitored by thin-layer chromatography on 0.25 mm E. Merck silica gel plates (60F-254), visualised with UV light, 5% ethanolic phosphomolybdic acid or p- anisaldehyde solution. Flash column chromatography was performed on silica gel (230- 400 mesh, Merck).
  • the title compound was prepared by the method of DeJong and Wibaut, Reel. Trav. Chim. Pays-Bas., 49 p.237-46 (1930).
  • a solution of 2,4-dimethylpyrroie (10g; 0.105mol) in glacial acetic acid (500ml) was hydrogenated at atmospheric pressure and ambient temperature over platinum oxide (2g). After 4h, a further 2g platinum oxide was added and the reaction continued overnight.
  • the catalyst was removed by filtration, and the resulting filtrate was basified strongly with potassium hydroxide pellets (with addition of ice and external card-ice/acetone cooling).
  • the product was obtained by steam distillation of the basic solution, followed by extraction with diethyl ether.
  • the title compound was prepared from fert-butylpropylamine (D36) (632mg; 5.5mmol) using the method outlined in Description 1 (40mg; 4% over 2 steps).
  • Potassium hydride (860mg; 30% in oil) was weighed into an oven dried 3-necked flask and stirred in THF (5ml) under an inert atmosphere during the addition of (2R.6S)- dimethylpiperidine (0.75ml) as a solution in THF (5ml). The suspension was stirred at room temperature for 2 hrs. S-(-)-Glycidyl nosylate (1.13g) was then added dropwise as a solution in THF (5ml) and the reaction mixture stirred at room temperature overnight. The reaction mixture was filtered under an inert atmosphere through CeliteTM and the organic solution evaporated to half volume at reduced pressure, m/z 170 (API + ) [MH + ].
  • 2,6-Diacetylpyridine (2g) was dissolved in diethyleneglycol (50ml) with hydrazine monohydrate (3.6ml). The reaction mixture was heated at 170°C for 30 min. The reaction mixture was then cooled to room temperature for the addition of potassium hydroxide (3.1g), then heated at 200°C for 2h when the reaction mixtue lost all colour. The reaction mixture was then cooled to room temperature and poured onto water.
  • Naphthalene-1 -sulfonic acid [(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-2-hydroxy- propylj-amide was prepared by the following procedure: (S)-1-Amino-3-piperidin-1- ylpropan-2-ol (D50; 117mg) was dissolved in dichloromethane (6ml) and 1- naphthylsulfonylchloride (185mg) and triethylamine (0.11ml) were added. The reaction mixture was stirred overnight, diluted with dichloromethane and washed with NaHCO 3 solution and brine. The organic solution was dried (MgSO 4 ), and evaporated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a compound of formula (I): or a salt, solvate or a physiologically functional derivative thereof, wherein R1 to R10 are as defined in the specification and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.

Description

GLYT1 TRANSPORTER INHIBITORS
The present invention relates to glycine transporter inhibiting compounds, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.
Molecular cloning has revealed the existence in mammalian brains of two classes of glycine transporters, termed GlyT1 and GlyT2. GlyT1 is found predominantly in the forebrain and its distribution corresponds to that of glutaminergic pathways and NMDA receptors (Smith, et. al., Neuron, 8, 1992: 927-935). Molecular cloning has further revealed the existence of three variants of GlyT1 , termed GlyT-la, GlyT-1 b and GlyT-1 c (Kim et al., Molecular Pharmacology, 45, 1994: 608-617), each of which displays a unique distribution in the brain and peripheral tissues. The variants arise by differential splicing and exon usage, and differ in their N-terminal regions. GlyT2, in contrast, is found predominantly in the brain stem and spinal cord, and its distribution corresponds closely to that of strychnine-sensitive glycine receptors (Liu et al., J. Biological Chemistry, 268, 1993: 22802-22808; Jursky and Nelson, J. Neurochemistry, 64, 1995 : 1026-1033). Another distinguishing feature of glycine transport mediated by GlyT2 is that it is not inhibited by sarcosine as is the case for glycine transport mediated by GlyT1. These data are consistent with the view that, by regulating the synaptic levels of glycine, GlyT1 and GlyT2 selectively influence the activity of NMDA receptors and strychnine-sensitive glycine receptors, respectively.
NMDA receptors are critically involved in memory and learning (Rison and Staunton, Neurosci. Biobehav. Rev.. 19 533-552 (1995); Danysz et al, Behavioral Pharmacol.. 6 455-474 (1995)); and, furthermore, decreased function of NMDA-mediated neurotransmission appears to underlie, or contribute to, the symptoms of schizophrenia (Olney and Farber, Archives General Psychiatry, 52, 998-1007 (1996). Thus, agents that inhibit GlyT1 and thereby increase glycine activation of NMDA receptors can be used as novel antipsychotics and anti-dementia agents, and to treat other diseases in which cognitive processes are impaired, such as attention deficit disorders and organic brain syndromes. Conversely, over-activation of NMDA receptors has been implicated in a number of disease states, in particular the neuronal death associated with stroke and possibly neurodegenerative diseases, such as Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis or other conditions in which neuronal cell death occurs, such as stroke or head trauma. Coyle & Puttfarcken, Science. 262. 689-695 (1993); Upton and Rosenberg, New Enαl. J. of Medicine. 330. 613-622 (1993); Choi, Neuron. 1 , 623-634 (1988). Thus, pharmacological agents that increase the activity of GlyT1 will result in decreased glycine- activation of NMDA receptors, which activity can be used to treat these and related disease states. Similarly, drugs that directly block the glycine site of the NMDA receptors can be used to treat these and related disease states.
Glycine transport inhibitors are already known in the art, for example as disclosed in published International Applications WO97/45423 (Trophix Pharmaceuticals, Inc.), and WO97/45115 (Trophix Pharmaceuticals Inc.). The classes of compounds disclosed in these applications inhibit glycine transport via the GlyTI or GlyT2 transporters.
In published International Application WO99/34790 (Allelix Neuroscience, Inc.), there is disclosed a class of compounds which also inhibits glycine transport via the GlyTI or GlyT2 transporters, with preferred compounds showing selectivity for the inhibition of glycine transport via GlyT2 versus GlyTI .
Further publications disclosing glycine transport inhibitors include published International Applications WO99/45011 (Janssen Pharmaceutica N.V.), WO00/07978 (Akzo Nobel N.V.) and WO01/87855 (Yamanouchi Pharmaceutical Co. Ltd.). Published International Applications WO01/32602 and WO01/81308 (both NPS Allelix Corp.) disclose classes of compounds which inhibit glycine transport (or reuptake) via the GlyTI transporter. Published International Applications WO01/36423 (Akzo Nobel N.V.) and WO03/55478 (SmithKline Beecham pic) disclose compounds that inhibit glycine transport by the human GlyTI transporter .
However, there still remains the need to identify further compounds that can inhibit GlyTI transporters, including those that inhibit GlyTI transporters selectively over GlyT2 transporters. Such compounds would thus be suitable for the treatment of certain neurological and neuropsychiatric disorders, including psychoses such as schizophrenia, dementia and other forms of impaired cognition such as attention deficit disorders and organic brain syndromes. Other neuropsychiatric disorders include drug-induced (phencyclidine, ketamine and other dissociative anaesthetics, amphetamine and other psychostimulants and cocaine) psychosis, psychosis associated with affective disorders, brief reactive psychosis, schizoaffective psychosis, and psychosis NOS, "schizophrenia- spectrum" disorders such as schizoid or schizotypal personality disorders, or illness associated with psychosis (such as major depression, manic depressive (bipolar) disorder, Alzheimer's disease and post-traumatic stress syndrome), and NMDA receptor- related disorders such as autism, depression, benign forgetfulness, childhood learning disorders and closed head injury.
It has now surprisingly been found that a class of compounds inhibit GlyTI transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia. Thus, in the first aspect, there is provided a compound of formula (I):
Figure imgf000005_0001
(I)
or a salt, solvate or a physiologically functional derivative thereof, wherein: (i) R1 and R2 are independently:
(a) a group -(CR11R12)n-A wherein R11 and R12 are independently hydrogen or C-,- C6 alkyl, n is 0 or 1 and A is hydrogen, optionally substituted C,-C6 alkyl, optionally substituted aryl or optionally substituted arylC1-C4 alkyl, wherein R1 and R2 are not both hydrogen; or
(b) a group
Figure imgf000005_0002
wherein m is 1 , 2, 3, 4 or 5 and R is hydrogen or Cι-C6 alkyl; or
(c) a group
Figure imgf000005_0003
wherein p is 1 , 2, 3, 4 or 5, R >14 : i,s hydrogen or C-i-Ce alkyl, and B is an optionally substituted aryl;
or (ii) R1 and R2, together with the nitrogen atom to which they are attached, form a group:
Figure imgf000005_0004
wherein Q is an optionally substituted 4-, 5-, 6- or 7-membered saturated ring, wherein one or more of the carbon atoms of the saturated ring is optionally replaced by a heteroatom independently selected from N, O and S, and R15, R16, R17and R18 are independently hydrogen or d-Ce alkyl; R3 is
/(Y)q Z ^ * wherein Y is C-|-C2 alkylene, C2 alkenylene or C2 alkynylene, q is 0 or 1 , and Z is a 5- to 7-membered optionally substituted monocyclic aromatic ring system or 6- to 11 -membered optionally substituted bicyclic aromatic ring system;
R4 and R5 are both hydrogen, or one of R4 and R5 is hydrogen and the other is: (a) -SO2R19 wherein R19 is a 5- to 7- membered optionally substituted monocyclic aromatic ring system or a 6- to 11- membered optionally substituted bicyclic aromatic ring system; or (b) -XR20 wherein X is -CO(CH2)r- (wherein r is 0, 1 , 2, 3 or 4) or -CONH- wherein R20 is hydrogen, Cι-C6 alkyl or a 5- to 7- membered optionally substituted monocyclic aromatic ring system or a 6- to 11- membered optionally substituted bicyclic aromatic ring system;
R6 is independently selected from hydrogen, Cι-C6alkyl, C3-C6cycloalkyl, C3- Cecycloalkyld-Cβalkyl, aryl and arylC-ι-C4 alkyl; and
R7, R8, R9 and R10 are independently selected from hydrogen, C.|-C6 alkyl, C3-C6 cycloalkyl, aryl or arylC1-C4 alkyl; or R7 and R8 together form a C3-C6 cycloalkyl group, and/or R9 and R10 together form a C3-C6 cycloalkyl group.
As used herein, the term "d.Ce alkyl" refers to a straight or branched chain hydrocarbon which contains at least 1 , and at most 6, carbon atoms. Examples of "C C6 alkyl" groups useful in the present invention include, but are not limited to, methyl, ethyl, n-propyl, i- propyl, n-butyl, i-butyl, t-butyl, n-pentyl and n-hexyl.
In a like manner, the term "d.C4 alkyl" refers to a straight or branched chain hydrocarbon which contains at least 1 , and at most 4, carbon atoms. Examples of "C C4 alkyl" groups useful in the present invention include, but are not limited to, methyl, ethyl, n-propyl, i- propyl, n-butyl, i-propyl and t-butyl. As used herein, the term "C3-C6 cycloalkyl" refers to a non-aromatic cyclic hydrocarbon ring having from three to six carbon atoms. Examples of "C3-C6 cycloalkyl" groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
As used herein, the term "C3-C6 cycloalkylC1-C4 alkyl" refers to a C3-C6 cycloalkyl group, as hereinbefore defined, attached through a C-ι-C4 alkylene linker, wherein C-ι-C4 alkylene is as defined herein. Examples of "C3-C6 cycloalkylC1-C4 alkyl" include, but are not limited to, cyclohexylmethyl.
As used herein, the term "aryl" refers to a 5- to 7-membered aromatic or heteroaromatic ring system wherein the heteroatomic ring contains at least one heteroatom selected from nitrogen, oxygen and sulphur. Examples of aryl groups include phenyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, oxadiazolyl, isothiazolyl, thiazolyl, furyl, thienyl, pyridyl, thiazinyl, pyridazinyl, pyrimidinyl, pyrazinyl and azepinyl.
As used herein, the term "arylC C4 alkyl" refers to an aryl group, as hereinbefore defined, attached through a C C4 alkylene linker, wherein C C4 alkylene is as defined herein. Examples of "arylC C4 alkyl" include, but are not limited to, benzyl, phenethyl, pyridylmethyl and phenylpropyl.
As used herein, the terms "Cι.C2 alkylene", "C-i.Cs alkylene" and "Cι,C4 alkylene" refer to a straight or branched chain divalent hydrocarbon radical, which contains at least 1 , and at most 2, 3 or 4, carbon atoms respectively. Examples of "d-C2 alkylene", "Cι_C3 alkylene" and "d.d alkylene" groups useful in the present invention include methylene, ethylene, n- propylene and n-butylene.
As used herein, the term "C2 alkenylene" refers to a divalent hydrocarbon radical with a double bond, which contains 2 carbon atoms.
As used herein, the term "C2 alkynylene" refers to a divalent hydrocarbon radical with a triple bond, which contains 2 carbon atoms.
As used herein, the terms "hal" and "halo" are abbreviations for "halogen" and refers to fluorine, chlorine, bromine, or iodine.
The term "5- to 7- membered monocyclic aromatic ring system" refers to a monocyclic aromatic ring system consisting of 5, 6 or 7 carbon atoms, wherein one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from nitrogen, oxygen and sulfur. Examples of such groups include: phenyl, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyrazolyl, isothiazolyl, thiazolyl, isoxazolyl, furazanyl, oxazolyl, furyl, thienyl, pyridyl, pyridazinyl, pyrimidinyl, oxadiazolyl, triazolyl, thiadiazolyl, pyrazinyl, triazinyl, azepinyl and pyranyl. The term "6- to 11- membered bicyclic aromatic ring system" refers to a bicyclic aromatic ring system consisting of 6, 7, 8, 9, 10 or 11 carbon atoms, wherein one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from nitrogen, oxygen and sulfur. The term includes bicyclic aromatic ring systems wherein both rings are aromatic, as well as bicyclic aromatic ring systems wherein one of the rings is partially or fully saturated. Examples of bicyclic aromatic ring systems in which both rings are aromatic include: naphthyl, indenyl, indolyl, isoindolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzothienyl, benzofuranyl, naphthridinyl, quinolyl, quinoxalinyl, quinazolinyl and isoquinolyl. Examples of bicyclic aryl groups in which one of the rings is partially or fully saturated includes dihydrobenzofuranyl, indanyl, tetrahydronaphthyl, indolinyl, isoindolinyl, tetrahydroisoquinolinyl, tetrahydroquinolyl, benzoxazinyl and benzoazepinyl.
All of these ring systems may be attached to the rest of the molecule via any available atom on the ring system, such as carbon or nitrogen.
As used herein, the term "salt" refers to any salt of a compound according to the present invention prepared from an inorganic or organic acid or base, quaternary ammonium salts and internally formed salts. Physiologically acceptable salts are particularly suitable for medical applications because of their greater aqueous solubility relative to the parent compounds. Such salts must clearly have a physiologically acceptable anion or cation. Suitably physiologically acceptable salts of the compounds of the present invention include acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, hydroiodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and with organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, formic, propionic, glycolic, gluconic, maleic, succinic, camphorsulfuric, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, stearic, sulfinilic, alginic, galacturonic and arylsulfonic, for example benzenesulfonic and p-toluenesulfonic, acids; base addition salts formed with alkali metals and alkaline earth metals and organic bases such as N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumaine (N-methylglucamine), lysine and procaine; and internally formed salts. Salts having a non-physiologically acceptable anion or cation are within the scope of the invention as useful intermediates for the preparation of physiologically acceptable salts and/or for use in non-therapeutic, for example, in vitro, situations.
As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or formula (la), or a salt or physiologically functional derivative thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid. Most preferably the solvent used is water.
As used herein, the term "physiologically functional derivative" refers to any pharmaceutically acceptable derivative of a compound of the present invention, for example, an ester or an amide, which upon administration to a mammal is capable of providing (directly or indirectly) a compound of the present invention or an active metabolite thereof. Such derivatives are clear to those skilled in the art, without undue experimentation, and with reference to the teaching of Burger's Medicinal Chemistry And Drug Discovery, 5th Edition, Vol 1 : Principles and Practice, which is incorporated herein by reference to the extent that it teaches physiologically functional derivatives.
Suitable substituents for groups in formula (I) which are optionally substituted include one or more groups selected from: halogen, hydroxy, oxo, cyano, nitro, C-j. alkyl, C-] ^alkoxy, haloci-4alkyl. haloC^alkoxy, arylCι_4alkoxy, C-|_4alkylthio, hydroxyC-^alkyl, C-μ
Figure imgf000009_0001
C<|_ 4alkoxycarbonyl, C-^alkylsulfonyl, C^alkylsulfonyloxy, Cl^alkylsulfonylC-j^alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC-^alkyl, C^alkylsulfonamido, C-|_4alkylamido, C-] _4alkylsulfonamidoCι _4alkyl, C-| _4alkylamidoC-| _4.alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC-|_4alkyl, arylcarboxamidoC^alkyl, aroyl, aroylC-j. 4alkyl, arylCι_4.alkanoyl, C-j^acyl, aryl, arylC<|_4alkyl, Cι_4alkylaminoC-|_4alky[, a group R21R22N-, R21OCO(CH2)r, R21CON(R22)(CH2)r, R21R22NCO(CH2)r, R21R22NSO2(CH2)r or R21SO2NR22(CH2)r (where each of R21 and R22 independently represents a hydrogen atom or a C-|_4alkyl group or where appropriate R21R22 forms part of a C3_Razacyloalkane or C3_β.(2-oxo)azacycloalkane ring and r represents zero or an integer from 1 to 4), a group R21R2 N(CH2)t- or R21R22N(CH2)tO- (wherein t represents an integer from 1 to 4); wherein when the substituent is R21R22N(CH2)t- or R21R22N(CH2)tO, R21 with at least one CH2 of the (CH2)t portion of the group may also form a C3_gazacycloalkane and R22 may represent hydrogen, a C^alkyl group or with the nitrogen to which it is attached, may form a second C3_gazacycloalkane fused to the first C3_gazacycloalkane; furthermore, the optionally substituted 4-, 5-, 6- or 7-membered saturated ring formed by R1 and R2 may be additionally optionally bridged by a d-C3 alkylene group; and the optionally substituted 4-, 5-, 6- or 7-membered saturated ring formed by R1 and R2 may be additionally optionally fused to a C5-C7 alicyclic or 5- or 6-membered aromatic or heteroaromatic ring optionally substituted by one or more groups independently selected from d-C6 alkyl and C3-C6 cycloalkyl. Where there is more than one substituent, the substituents may be different or the same. If substituent(s) is/are present, preferably the number of substituent(s) is 1 , 2, 3 or 4. Certain of the compounds described herein may exist in stereoisomeric forms (i.e. they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism). The individual stereoisomers (enantiomers and diastereoisomers) and mixtures of these are included within the scope of the present invention. Likewise, it is understood that compounds of formulae (I) and (la) may exist in tautomeric forms other than that shown in the formulae and these are also included within the scope of the present invention.
As referred to above, individual enantiomers of compounds of formulae (I) and (la) may be prepared and an indication of the preferred stereochemistry for such enantiomers has been given. In a preferred embodiment, an optically pure enantiomer is desired. The term "optically pure enantiomer" means that the compound contains greater than about 90 % of the desired isomer by weight, preferably greater than about 95 % of the desired isomer by weight, and most preferably greater than about 99 % of the desired isomer by weight, said weight percent based upon the total weight of the isomer(s) of the compound.
Preferably, the compound of formula (I) as hereinbefore described has the following stereochemical configuration:
Figure imgf000010_0001
It will be understood by the skilled artisan that the stereochemical configuration at the chiral centre marked with a * will be assigned the Cahn-lngold-Prelog notation of (R).
In one embodiment of the present invention, R1 and R2 are independently selected from optionally substituted d-C6 alkyl, preferably C3-C6 alkyl such as isopropyl. The optional substituents for the d-C6 alkyl may be one, two or three groups selected from: halogen, C-|_6alkyl, C^alkoxy, haloci-4alkyl, haloC-]_4alkoxy, C-|_4alkylsulfonamidoCι_4alkyl, Cι_4alkylamidoC-|_4alkyl, aryl, arylC-j^alkyl, a group R21CON(R22)(CH2)r, R21R22NCO(CH2)r, R21R22NSO2(CH2)r or R21SO2NR22(CH2)r (where each of R21 and R22 independently represents a hydrogen atom or a C<|_4alkyl group or where appropriate R21R22 forms part of a C3_Razacyloalkane or C3_6(2-oxo)azacycloalkane ring and r represents zero or an integer from 1 to 4).
In another embodiment, R1 and R2 together with the nitrogen atom to which they are attached are linked to form a 4-, 5-, 6- or 7-membered heterocyclic ring, wherein the sole heteroatom is the nitrogen atom to which R1 and R2 are attached, said ring being optionally substituted by one, two or three groups selected from: halogen, Chalky!, C-j. 4alkoxy, haloci-4alky[, haloC^alkoxy, C^alkylsulfonamidoC-^alkyl, C-|.
4alkylamidoC1.4alkyl, aryl, arylC^alkyl, a group R21CON(R22)(CH2)r, R21R22NCO(CH2)r, R21R22NSO2(CH2)r or R21SO2NR22(CH2)r (where each of R21 and R22 independently represents a hydrogen atom or a C-|_4alkyl group or where appropriate R21R22 forms part of a C3_6azacyloalkane or C3_6(2-oxo)azacycloalkane ring and r represents zero or an integer from 1 to 4), said ring being further optionally fused to a C5-C7 alicyclic or 5- or 6- membered aromatic or heteroaromatic ring as hereinbefore described.
In another embodiment, R1 and R2 together with the nitrogen atom to which they are attached are linked to form a 5- or 6-membered ring, wherein one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from N, O and S, said ring being optionally substituted by one, two or three groups selected from: halogen,
C-|.galkyl, C-^alkoxy, haloQ-^alkyl, haloC^alkoxy, C-^alkylsulfonamidoC-^alkyl,
C<|_4alkylamidoCι_4alkyl, aryl, arylC^alkyl, a group R21CON(R22)(CH2)r, R21R22NCO(CH2)r, R21R22NSO2(CH2)r or R21SO2NR22(CH2)r (where each of R21 and R22 independently represents a hydrogen atom or a C-|_4alkyl group or where appropriate
R21R22 forms part of a C3_βazacyloalkane or C3_6(2-oxo)azacycloalkane ring and r represents zero or an integer from 1 to 4), said ring being further optionally fused to a C5-
C7 alicyclic or 5- or 6-membered aromatic or heteroaromatic ring as hereinbefore described.
In another embodiment, R1 and R2 together with the nitrogen atom to which they are attached are linked to form a 5- or 6-membered heterocyclic ring, wherein the sole heteroatom is the nitrogen atom to which R1 and R2 are attached, said ring being optionally substituted by one, two or three groups selected from: halogen, C-ι_galkyl, C-|. 4alkoxy, haloci-4alkyl, haloC-] ^alkoxy, C-i^alkylsulfonamidoC-i^alkyl, C-|_
4alkylamidoC-|.4alkyl, aryl, arylC^alkyl, a group R21CON(R22)(CH2)r, R21R NCO(CH2)r, R21R22NSO2(CH2)r or R21SO2NR 2(CH2)r (where each of R21 and R22 independently represents a hydrogen atom or a C-^alkyl group or where appropriate R21R22 forms part of a C3_gazacyloalkane or C3_g(2-oxo)azacycloalkane ring and r represents zero or an integer from 1 to 4), preferably by one or more groups independently selected from optionally substituted d-C6 alkyl and optionally substituted C3-C6 cycloalkyl, more preferably by one or more groups independently selected from C1-C alkyl, most preferably methyl, ethyl or isopropyl.
Suitably, the 4-, 5-, 6- or 7-membered saturated ring formed by R1 and R2 together with the nitrogen atom to which they are linked is selected from the group comprising: azetidine, azepine, pyrrolidine, imidazolidine, piperidine, morpholine, thiomorpholine, piperazine, all of which being optionally substituted by one, two or three groups selected from: halogen, C^.galkyl, C-j ^alkoxy, haloci-4.alkyl, haloC-] ^alkoxy, C^_
4alkylsulfonamidoC-|_4alkyl, C^alkylamidoC^alkyl, aryl, arylC-i^alkyl, a group R21CON(R22)(CH2)r, R21R22NCO(CH2)r, R2 R22NSO2(CH2)r or R21SO2NR22(CH2)r (where each of R21 and R22 independently represents a hydrogen atom or a C-i^alkyl group or where appropriate R21R22 forms part of a C3_eazacyloalkane or C^.Q(2- oxo)azacycloalkane ring and r represents zero or an integer from 1 to 4).
In another embodiment, R1 and R2 together with the nitrogen atom to which they are attached are linked to form a pyrrolidinyl ring, said ring being optionally substituted by one or more groups independently selected from optionally substituted C1-C4 alkyl, preferably methyl, ethyl or isopropyl. Preferably, the pyrrolidinyl ring formed by R1 and R2 together with the nitrogen atom to which they are attached is substituted by one or more d-C4 alkyl groups, preferably methyl, ethyl or isopropyl groups, preferably at the 2- and/or 5- positions, more preferably at the 2-position.
In another embodiment, R1 and R2 together with the nitrogen atom to which they are attached are linked to form a piperidinyl ring, said ring being optionally substituted by one or more groups independently selected from optionally substituted C1-C4 alkyl, preferably methyl or ethyl. Preferably, the piperidinyl ring formed by R1 and R2 together with the nitrogen atom to which they are attached is substituted by one or more methyl or ethyl groups, preferably at the 2- and 6-positions. More preferably, the piperidinyl ring formed by R1 and R2 together with the nitrogen atom to which they are attached is substituted by two methyl groups, preferably at the 2- and 6- positions.
In one embodiment of the present invention, q is 0.
In one embodiment, Z is substituted by 1 , 2 or 3 groups independently selected from: - hal, -R23, -OR24, -C(O)OR25, -CN, -NO2, -NR26R27, -C(O)NR28R29, -NR30C(O)R31, - C(O)R32, -C(NR33)NR34R35, -C(NOR36)R37, or C<|_6alkylsulphonyl; wherein R23 is d-C6 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylC1-C4 alkyl, aryl, aryloxy or arylC1-C4 alkyl, all of which being optionally substituted by one or more groups independently selected from hal, d-C6 alkyl, -OR24, -COOR25 -CN, -NO2 and -NR26R27, wherein R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36 and R37 are independently selected from hydrogen and Cι-C6 alkyl.
In one embodiment, Z is a 5- to 7-membered optionally substituted monocyclic aromatic ring system as hereinbefore described. Suitably, Z is a 5- or 6-membered optionally substituted monocyclic ring system as hereinbefore described. Suitably, Z is phenyl optionally substituted as hereinbefore described, preferably by one or more groups independently selected from -hal, -R10, -CF3, -C-|-C6alkylsulphonyl, -OR11, -COOR12, -CN, -NO2, -NR13R14 as hereinbefore defined, more preferably by one or more groups independently selected from -hal, d-C6 alkyl, d-C6 alkoxy, CF3, -CN and C3-C6 cycloalkyl. In another embodiment, Z is a 6- to 11 -membered optionally substituted bicyclic aromatic ring system as hereinbefore described. Suitably, Z is a 8- to 10- membered optionally substituted bicyclic aromatic ring system as hereinbefore described. Suitably, Z is selected from the group comprising: naphthyl, naphthyridinyl, quinolinyl, isoquinolyl, benzothienyl, chromanyl, chromenyl, imidazoleisothiazolyl, benzothiadiazolyl, benzofuryl, all of which being optionally substituted as hereinbefore described. Preferably, Z is quinolinyl (preferably 5-quinolinyl), optionally substituted as hereinbefore described, preferably by one or more groups independently selected from -hal, -R23, -OR24, - COOR25, -CF3, -Ci-Cβalkylsulphonyl, -CN, -NO2, and -NR26R27, wherein hal, R23, R24, R25, R26 and R27 are as hereinbefore defined, preferably hal, d-C6 alkyl, Ci-Ce alkoxy, CF3, -CN and C3-C6 cycloalkyl. Most preferably, Z is 5-quinolinyl optionally substituted by one or more groups independently selected from -hal, d-C6 alkyl, d-C6 alkoxy, - CF3, -CN and C3-C6 cycloalkyl.
Preferably, R3 is phenyl or 5-quinolinyl.
In one embodiment, one of R4 and R5 is hydrogen and the other is a group -COCH2R38, - COR38 or -CONHR38 wherein R38 is a 5- to 7- membered monocylic aromatic ring system or a 6- to 11- membered bicyclic aromatic ring system, said ring system being optionally substituted by one or two groups independently selected from hal, CF3, d-C6alkyl, d- C6alkoxy,-CN, d-Cealkylamido, d-C6alkanoyl and d-C6alkylsulphonyl.
In another embodiment, R6 is selected from hydrogen, d-C6 alkyl, aryl and benzyl, wherein the d~C6 alkyl, aryl and benzyl are optionally substituted by one or more groups independently selected from hal, d-C6 alkyl, hydroxy and d-C6 alkoxy. Preferably, R6 is hydrogen.
In one embodiment, R7, R8, R9 and R10 are independently selected from hydrogen and Ci- Ce alkyl, preferably hydrogen.
In a further aspect of the present invention, there is provided a compound of formula (la):
Figure imgf000013_0001
or a salt or solvate or a physiologically functional derivative thereof, wherein: R39 and R40 are independently selected from C3-C6 alkyl, or
R39 and R40, together with the nitrogen atom to which they are attached, are linked to form a 5-, 6-, or 7- membered heterocyclic ring, wherein the sole heteroatom is the nitrogen atom to which R39 and R40 are attached, said heterocyclic ring being optionally substituted by one or more groups independently selected from C1-C4 alkyl and C3-C6 cycloalkyl, and said heterocyclic ring being further optionally fused to a C6 alicyclic or aromatic ring, and said heterocyclic ring being further optionally bridged by a methylene group; R41 is C=C- L H H wherein a is 0 or 1 , and Zi is a 5- or 6-membered monocyclic aromatic ring system or a 6- to 10-membered bicyclic aromatic ring system, said ring system being optionally substituted by one or more groups independently selected from -hal, -R44, -OR45, -COOR46, -CN, - NO2, -NR 7R48, wherein R44 is C1-C4 alkyl or phenyl optionally substituted by one or more hal groups and R45, R , R 347 and R j48 are independently selected from hydrogen and methyl,
one of R42 and R43 is hydrogen and the other is a group -X1R49, wherein X-, is CONH- or - CO(CH2)b- wherein b is 0, 1 or 2, and R49 is a 5- to 6-membered monocylic aromatic ring system or a 6- to 10- membered bicyclic aromatic ring system, said ring system being optionally substituted by one, two or three groups independently selected from -hal, -R50, -OR51, -C(O)OR52, -CN, -NO2, -NR53R54, -C(O)NR55R56, -NR57C(O)R58, -C(O)R59, - C(NR60)NR6 R62, -C(NOR63)R64, or C-|.6alkylsulphonyl, wherein R50 is d-C6 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylC1-C4 alkyl, aryl, aryloxy or arylC1-C4 alkyl, all of which being optionally substituted by one or more groups independently selected from hal, C|-C6 alkyl, -OR51, -COOR52, -CN, -NO2 and -NR53R54; wherein R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63 and R64 are independently selected from hydrogen and Ci- Ce alkyl.
When a is 1 , the C2 alkenylene group may be in the cis or trans configuration, preferably the trans configuration. Preferably a is 0.
In a further embodiment, the compound of formula (la) as hereinbefore described has the following stereochemical configuration:
Figure imgf000014_0001
It will be understood by the skilled artisan that the stereochemical configuration at the chiral centre marked with a * will be assigned the Cahn-Ingold-Prelog notation of (R).
Preferred features of formula (I) apply to formula (1a) mutatis mutandis.
Examples of preferred compounds of the invention include Examples 1 to 42 shown below, as well as salts, solvates and physiologically functional derivatives thereof:
Ex 1 Naphthalene-1-sulfonic acid [(R)-2-amino-3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)- propylj-amide
Ex 2 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-acetamide EX 3 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-benzamide Ex 4 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-butyramide Ex 5 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-2-phenyl-acetamide Ex 6 Thiophene-2-carboxylic acid {(R)-2-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)-1 - [(naphthalene-1 -sulfonylamino)-methyl]-ethyl}-amide
Ex 7 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-4-methanesulfonyl-benzamide Ex 8 4-bromo-Λ/-{(R)-2-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)-1 -[(naphthalene-1 - sulfonylamino)-methyl]-ethyl}-benzamide Ex 9 Naphthalene-2-carboxylic acid {(R)-2-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-1- [(naphthalene-1-sulfonylamino)-methyl]-ethyl}-amide Ex 10 Benzo[1 ,3]dioxole-5-carboxylic acid {(R)-2-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)-1 - [(naphthalene-1-sulfonylamino)-methyl]-ethyl}-amide Ex 11 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-3-methoxy-benzamide
Ex 12 3,5-Dichloro-/V-{(R)-2-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 - sulfonylamino)-methyl]-ethyl}-benzamide Ex 13 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-3-methanesulfonyl-benzamide Ex 14 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-2-methanesulfonyl-benzamide Ex 15 Λ/-{(R)-2-((2R,6S)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-4-methoxy-benzamide Ex 16 Λ/-{(R)-2-((2R,6S)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-terephthalamic acid methyl ester
Ex 17 4-Acetyl -Λ/-{(R)-2-((2R,6S)-2,6-dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 - sulfonylamino)-methyl]-ethyl}-benzamide Ex 18 4-cyano -Λ/-{(R)-2-((2R,6S)-2,6-dimethyl-piperidin-1 -yl)-1 -[(naphthalene-1 - sulfonylamino)-methyl]-ethyl}-benzamide Ex 19 4-Acetylamino -Λ/-{(R)-2-((2R,6S)-2,6-dimethyl-piperidin-1 -y|)-1 -[(naphthalene-1 - sulfonylamino)-methyl]-ethyl}-benzamide Ex 20 Λ/-{(R)-2-((2R,6S)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-2-(4-methanesulfonyl-phenyl)-acetamide Ex 21 Λ/-[(R)-1-(Benzenesulfonylamino-methyl)-2-((2S,6R)-2,6-dimethyl-piperidin-1-yl)- ethyl]-4-methanesulfonyl-benzamide Ex 22 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(quinoline-5-sulfonylamino)- methyl]-ethyl}-4-methanesulfonyl-benzamide
Ex 23 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(5-fluoro-2-methyl- benzenesulfonylamino)-methyl] -ethyl}-4-methanesulfonyl-benzamide Ex 24 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(4-methoxy- benzenesulfonylamino)-methyl]-ethyl}-4-methanesulfonyl-benzamide Ex 25 -{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1-[(naphthalene-2-sulfonylamino)- methyl]-ethyl}-4-methanesulfonyl-benzamide Ex 26 Λ/-[(R)-1 -[(5-Cyano-naphthalene-1 -sulfonylamino)-methyl]-2-((2S,6R)-2,6-dimethyl- piperidin-1-yl)-ethyl]-4-methanesulfonyl-benzamide Ex 27 Λ/-[(R)-1 -(Benzenesulfonylamino-methyl)-2-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)- ethyl]-4-methoxy-benzamide
Ex 28 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(quinoline-5-sulfonylamino)- methyl]-ethyl}-4-methoxy-benzamide Ex 29 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(5-fluoro-2-methyl- benzenesulfonylamino)-methyl] -ethyl}-4-methoxy-benzamide Ex 30 A/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1-[(4-methoxy- benzenesulfonylamino)-methyl]-ethyl}-4-methoxy-benzamide Ex 31 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(naphthalene-2-sulfonylamino)- methyl]-ethyl}-4-methoxy-benzamide Ex 32 Λ/-[(R)-1 -[(5-Cyano-naphthalene-1 -sulfonylamino)-methyl]-2-((2S,6R)-2,6-dimethyl- piperidin-1 -yl)-ethyl]-4-methoxy-benzamide
Ex 33 Naphthalene-1 -sulfonic acid [(R)-2-benzenesulfonylamino-3-((2S,6R)-2,6- dimethyl-piperidin-1-yl)-propyl]-amide Ex 34 Naphthalene-1 -sulfonic acid [(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)-2- (toluene-4-sulfonylamino) -propylj-amide Ex 35 Naphthalene-1 -sulfonic acid [(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-2-(4- methoxy-benzenesulfonylamino)-propyl]-amide Ex 36 Naphthalene-1 -sulfonic acid [(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)-2-(4- methanesulfonyl-benzenesulfonylamino)-propyl]-amide Ex 37 Naphthalene-1 -sulfonic acid [(R)-2-(3,5-dichloro-benzenesulfonylamino)-3- ((2S,6R)-2,6-dimethyl-piperidin-1 -yl)-propyl]-amide
Ex 38 Naphthalene-1 -sulfonic acid [(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-2-(3- phenyl-ureido)-propyl] -amide Ex 39 Naphthalene-1 -sulfonic acid {(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)-2-[3-(4- methoxy-phenyl)-ureido]-propyl}-amide Ex 40 Naphthalene-1 -sulfonic acid {(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)-2-[3-(4- trifluoromethyl-phenyl)-ureido]-propyl}-amide Ex 41 Naphthalene-1 -sulfonic acid {(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-2-[3-(3- trifluoromethyl-phenyl)-ureido]-propyl}-amide Ex 42 Naphthalene-1 -sulfonic acid [(R)-2-[3-(2,3-dichloro-phenyl)-ureido]-3-((2S,6R)-2,6- dimethyl-piperidin-1-yl)-propyl]-amide
The compounds of formulae (I) and (la) have the ability to crystallise in more than one form, a characteristic, which is known as polymorphism, and it is understood that such polymorphic forms ("polymorphs") are within the scope of formulae (I) and (la). Polymorphism generally can occur as a response to changes in temperature or pressure or both and can also result from variations in the crystallisation process. Polymorphs can be distinguished by various physical characteristics known in the art such as x-ray diffraction patterns, solubility, and melting point.
It is to be understood that the following embodiments refer to compounds within the scope of both formula (I) and formula (la) as defined above unless specifically limited by the definition of each formula or specifically limited otherwise. It is also understood that the embodiments of the present invention described herein, including uses and compositions, are applicable to both formula (I) and formula (la).
The compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working
Examples.
Compounds of general formula (I) or formula (la) may be prepared by methods disclosed in the documents hereinbefore referred to and by methods known in the art of organic synthesis as set forth in part by the following synthesis schemes. Generally, the following schemes are illustrated using compounds of formula (la), but it is recognised that such schemes are easily adaptable by the skilled artisan to prepare compounds of formula (I).
It is also recognised that in all of the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Greene and P. G. M. Wuts
(1991) Protecting Groups in Organic Synthesis, John Wiley & Sons). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection of processes as well as the reaction conditions and order of their execution shall be consistent with the preparation of compounds of formula (I) or (la). Those skilled in the art will recognise if a stereocentre exists in compounds of formula (I) or (la). Accordingly, the present invention includes both possible stereoisomers and includes not only racemic compounds but the individual enantiomers as well. Where the stereochemistry is indicated as being variable at certain positions, a mixture of stereoisomers may be obtained, this mixture having been separated where indicated. Stereoisomers may be separated by high-performance liquid chromatography or other appropriate means. When a compound is desired as a single enantiomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be effected by any suitable method known in the art. See, for example, Stereochemistry of Organic Compounds by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-lnterscience, 1994).
Typical reaction routes for the preparation of a compound of formula (I) as hereinbefore defined, wherein R4, R5, R6, R7, R8, R9 and R10 are hydrogen, are shown in Schemes 1 and 2.
Scheme 1 Scheme 2
Figure imgf000019_0001
/ THF
Figure imgf000019_0002
R3-S02CI DCM
lphonyl chloride + triethylamine DMF
Figure imgf000019_0003
0)
In Scheme 1 , the compounds of formula (A) may be prepared using methodology similar to that described by Gutcait A. et. al., Tetrahedron Asymmetry, 1996, 7(6), 1641-1648. Compounds of formula (A) may be converted to compounds of formula (I) above by displacement of the hydroxyl with azide, as shown above.
In Scheme 2, the reduction of the azide may be carried out using all methods known to those skilled in the art, for example, hydrogenation in the presence of catalyst such as palladium on carbon, Pd(OH)2 and those known in the art, see for example March, Advanced Organic Chemistry, 4th edition, Wiley Interscience. The reduction of the azide is preferably carried out by hydrogenation in the presence of a catalyst such as palladium on carbon.
As indicated above, Schemes 1 and 2 can be adapted to prepare compounds wherein R6, R7, R8, R9 and R10 are other than hydrogen.
Thus, in a further aspect of the invention, there is provided a process for the preparation of the compound of formula (I) as hereinbefore defined, by:
(a) reacting a compound of formula (II)
Figure imgf000020_0001
wherein R1, R2, R4, R5, R6, R7, R8, R10 and R9 are as hereinbefore defined, with a compound of formula (III)
RJSO2L (III)
wherein R3 is as hereinbefore defined and L is a suitable leaving group, such as, for example, a halogen, preferably chlorine; or
(b) converting a compound of formula (IV)
Figure imgf000020_0002
(IV) wherein R\ R2, R3, R6, R7, R8, R9 and R10 are as defined for formula (I); and thereafter optionally for process (a) or process (b):
• converting a compound of formula (I) into another compound of formula (I); or
• removing any protecting groups; or • forming a pharmaceutically acceptable salt, solvate or a physiologically functional derivative thereof.
Compounds of the present invention are useful for treating certain neurological and neuropsychiatric disorders. Thus, the present invention provides a compound of formula (I) or formula (1a) as hereinbefore described and salts, solvates and physiologically functional derivatives thereof, for use in therapy. In particular, the present invention provides a compound of formula (I) or formula (1a) as hereinbefore described and salts, solvates and physiologically functional derivatives thereof, for use in treating a disorder mediated by GlyTI .
In a further aspect of the invention, there is provided a method of treating a mammal, including a human, suffering from or susceptible to a disorder mediated by GlyTI , which comprises administering an effective amount of a GlyTI inhibiting compound of formula (I) or (la) as hereinbefore defined or a salt, solvate or a physiologically functional derivative thereof.
As used herein, the terms "therapy" and "treatment" refer to alleviation and/or cure of established symptoms as well as prophylaxis.
As used herein, the term "an effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
The present invention also provides the use of a compound of formula (I) or formula (la) as hereinbefore defined or a salt, solvate or a physiologically functional derivative thereof in the preparation of a medicament for the treatment of a disorder mediated by GlyTI .
As used herein, the term "a disorder mediated by GlyTI" refers to a disorder that may be treated by the administration of a medicament that alters the activity of the GlyTI transporter. As hereinbefore described, the action of GlyTI transporters affects the local concentration of glycine around NMDA receptors. As a certain amount of glycine is needed for the efficient functioning of NMDA receptors, any change to that local concentration can affect NMDA-mediated neurotransmission. As hereinbefore described, changes in NMDA-mediated neurotransmission have been implicated in certain neuropsychiatric disorders such as dementia, depression and psychoses, for example schizophrenia, and learning and memory disorders, for example attention deficit disorders and autism. Thus, alterations in the activity of the GlyTI transporter are expected to influence such disorders.
The disorders mediated by GlyTI referred to herein include neurological and neuropsychiatric disorders, including psychoses such as schizophrenia, dementia and other forms of impaired cognition such as attention deficit disorders and organic brain syndromes. Other neuropsychiatric disorders include drug-induced (phencyclidine, ketamine and other dissociative anesthetics, amphetamine and other psychostimulants and cocaine) psychosis, psychosis associated with affective disorders, brief reactive psychosis, schizoaffective psychosis, and psychosis NOS, "schizophrenia-spectrum" disorders such as schizoid or schizotypal personality disorders, or illness associated with psychosis (such as major depression, manic depressive (bipolar) disorder, Alzheimer's disease and post-traumatic stress syndrome), and NMDA receptor-related disorders such as autism, depression, benign forgetfulness, childhood learning disorders and closed head injury.
Preferably, the disorders mediated by GlyTI to be treated by the use or method as hereinbefore described are psychoses, including schizophrenia, dementia and attention deficit disorders, particularly schizophrenia.
Compounds for use according to the invention may be administered as the raw material but the active ingredients are preferably provided in the form of pharmaceutical compositions.
Accordingly, in a further aspect of the invention, there is provided a pharmaceutical composition comprising as active ingredient the compound of formula (I) or formula (la) as hereinbefore described, or a salt, solvate or a physiologically functional derivative thereof, and at least one pharmaceutically acceptable carrier, diluent or excipient.
These pharmaceutical compositions may be used in the treatment of clinical conditions for which a GlyTI inhibitor is indicated such as, for example, schizophrenia. The carrier must be pharmaceutically acceptable to the recipient and must be compatible with, i.e. not have a deleterious effect upon, the other ingredients in the composition. The carrier may be a solid or a liquid and is preferably formulated with at least one compound of formula (I) or (la) as hereinbefore described as a unit dose formulation. If desired, other physiologically active ingredients may also be incorporated in the pharmaceutical compositions of the invention.
Within the context of the present invention, the terms used herein are classified in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, published by the
American Psychiatric Association (DSM-IV) and/or the International Classification of
Diseases, 10th Edition (ICD-10). The various subtypes of the disorders mentioned herein are contemplated as part of the present invention. Numbers in brackets after the listed diseases below refer to the classification code in DSM-IV.
In particular, the compounds of formula (I) are of use in the treatment of schizophrenia including the subtypes Paranoid Type (295.30), Disorganised Type (295.10), Catatonic Type (295.20), Undifferentiated Type (295.90) and Residual Type (295.60); Schizophreniform Disorder (295.40); Schizoaffective Disorder (295.70) including the subtypes Bipolar Type and Depressive Type; Delusional Disorder (297.1) including the subtypes Erotomanic Type, Grandiose Type, Jealous Type, Persecutory Type, Somatic Type, Mixed Type and Unspecified Type; Brief Psychotic Disorder (298.8); Shared Psychotic Disorder (297.3); Psychotic Disorder Due to a General Medical Condition including the subtypes With Delusions and With Hallucinations; Substance-Induced Psychotic Disorder including the subtypes With Delusions (293.81) and With Hallucinations (293.82); and Psychotic Disorder Not Otherwise Specified (298.9).
The compounds of formula (I) are also of use in the treatment of mood disorders including Major Depressive Episode, Manic Episode, Mixed Episode and Hypomanic Episode; Depressive Disorders including Major Depressive Disorder, Dysthymic Disorder (300.4), Depressive Disorder Not Otherwise Specified (311); Bipolar Disorders including Bipolar I Disorder, Bipolar II Disorder (Recurrent Major Depressive Episodes with Hypomanic Episodes) (296.89), Cyclothymic Disorder (301.13) and Bipolar Disorder Not Otherwise Specified (296.80); Other Mood Disorders including Mood Disorder Due to a General Medical Condition (293.83) which includes the subtypes With Depressive Features, With Major Depressive-like Episode, With Manic Features and With Mixed Features), Substance-Induced Mood Disorder (including the subtypes With Depressive Features, With Manic Features and With Mixed Features) and Mood Disorder Not Otherwise Specified (296.90).
The compounds of formula (I) are also of use in the treatment of anxiety disorders including Panic Attack, Agoraphobia, Panic Disorder, Agoraphobia Without History of Panic Disorder (300.22), Specific Phobia (300.29) including the subtypes Animal Type, Natural Environment Type, Blood-lnjection-lnjury Type, Situational Type and Other Type), Social Phobia (300.23), Obsessive-Compulsive Disorder (300.3), Posttraumatic Stress Disorder (309.81), Acute Stress Disorder (308.3), Generalized Anxiety Disorder (300.02), Anxiety Disorder Due to a General Medical Condition (293.84), Substance-Induced Anxiety Disorder and Anxiety Disorder Not Otherwise Specified (300.00).
The compounds of formula (I) are also of use in the treatment of substance-related disorders including Substance Use Disorders such as Substance Dependence and Substance Abuse; Substance-Induced Disorders such as Substance Intoxication, Substance Withdrawal, Substance-Induced Delirium, Substance-Induced Persisting Dementia, Substance-Induced Persisting Amnestic Disorder, Substance-Induced Psychotic Disorder, Substance-Induced Mood Disorder, Substance-Induced Anxiety Disorder, Substance-Induced Sexual Dysfunction, Substance-Induced Sleep Disorder and Hallucinogen Persisting Perception Disorder (Flashbacks); Alcohol-Related Disorders such as Alcohol Dependence (303.90), Alcohol Abuse (305.00), Alcohol Intoxication (303.00), Alcohol Withdrawal (291.81), Alcohol Intoxication Delirium, Alcohol Withdrawal Delirium, Alcohol-Induced Persisting Dementia, Alcohol-Induced Persisting Amnestic Disorder, Alcohol-Induced Psychotic Disorder, Alcohol-Induced Mood Disorder, Alcohol- Induced Anxiety Disorder, Alcohol-Induced Sexual Dysfunction, Alcohol-Induced Sleep Disorder and Alcohol-Related Disorder Not Otherwise Specified (291.9); Amphetamine (or Amphetamine-Like)-Related Disorders such as Amphetamine Dependence (304.40), Amphetamine Abuse (305.70), Amphetamine Intoxication (292.89), Amphetamine Withdrawal (292.0), Amphetamine Intoxication Delirium, Amphetamine Induced Psychotic Disorder, Amphetamine-Induced Mood Disorder, Amphetamine-Induced Anxiety Disorder, Amphetamine-Induced Sexual Dysfunction, Amphetamine-Induced Sleep Disorder and Amphetamine-Related Disorder Not Otherwise Specified (292.9); Caffeine Related Disorders such as Caffeine Intoxication (305.90), Caffeine-Induced Anxiety Disorder, Caffeine-Induced Sleep Disorder and Caffeine-Related Disorder Not Otherwise Specified (292.9); Cannabis-Related Disorders such as Cannabis Dependence (304.30), Cannabis Abuse (305.20), Cannabis Intoxication (292.89), Cannabis Intoxication Delirium, Cannabis-lnduced Psychotic Disorder, Cannabis-lnduced Anxiety Disorder and Cannabis- Related Disorder Not Otherwise Specified (292.9); Cocaine-Related Disorders such as Cocaine Dependence (304.20), Cocaine Abuse (305.60), Cocaine Intoxication (292.89), Cocaine Withdrawal (292.0), Cocaine Intoxication Delirium, Cocaine-Induced Psychotic Disorder, Cocaine-Induced Mood Disorder, Cocaine-Induced Anxiety Disorder, Cocaine- Induced Sexual Dysfunction, Cocaine-Induced Sleep Disorder and Cocaine-Related Disorder Not Otherwise Specified (292.9); Hallucinogen-Related Disorders such as Hallucinogen Dependence (304.50), Hallucinogen Abuse (305.30), Hallucinogen Intoxication (292.89), Hallucinogen Persisting Perception Disorder (Flashbacks) (292.89), Hallucinogen Intoxication Delirium, Hallucinogen-Induced Psychotic Disorder, Hallucinogen-Induced Mood Disorder, Hallucinogen-Induced Anxiety Disorder and Hallucinogen-Related Disorder Not Otherwise Specified (292.9); Inhalant-Related Disorders such as Inhalant Dependence (304.60), Inhalant Abuse (305.90), Inhalant Intoxication (292.89), Inhalant Intoxication Delirium, Inhalant-Induced Persisting Dementia, Inhalant-Induced Psychotic Disorder, Inhalant-Induced Mood Disorder, Inhalant-Induced Anxiety Disorder and Inhalant-Related Disorder Not Otherwise Specified (292.9); Nicotine-Related Disorders such as Nicotine Dependence (305.1), Nicotine Withdrawal (292.0) and Nicotine-Related Disorder Not Otherwise Specified (292.9); Opioid-Related Disorders such as Opioid Dependence (304.00), Opioid Abuse (305.50), Opioid Intoxication (292.89), Opioid Withdrawal (292.0), Opioid Intoxication Delirium, Opioid-lnduced Psychotic Disorder, Opioid-lnduced Mood Disorder, Opioid-lnduced Sexual Dysfunction, Opioid-lnduced Sleep Disorder and Opioid-Related Disorder Not Otherwise Specified (292.9); Phencyclidine (or Phencyclidine-Like)-Related Disorders such as Phencyclidine Dependence (304.60), Phencyclidine Abuse (305.90), Phencyclidine Intoxication (292.89), Phencyclidine Intoxication Delirium, Phencyclidine- Induced Psychotic Disorder, Phencyclidine-lnduced Mood Disorder, Phencyclidine- Induced Anxiety Disorder and Phencyclidine-Related Disorder Not Otherwise Specified (292.9); Sedative-, Hypnotic-, or Anxiolytic-Related Disorders such as Sedative, Hypnotic, or Anxiolytic Dependence (304.10), Sedative, Hypnotic, or Anxiolytic Abuse (305.40), Sedative, Hypnotic, or Anxiolytic Intoxication (292.89), Sedative, Hypnotic, or Anxiolytic Withdrawal (292.0), Sedative, Hypnotic, or Anxiolytic Intoxication Delirium, Sedative, Hypnotic, or Anxiolytic Withdrawal Delirium, Sedative-, Hypnotic-, or Anxiolytic-Persisting Dementia, Sedative-, Hypnotic-, or Anxiolytic- Persisting Amnestic Disorder, Sedative-, Hypnotic-, or Anxiolytic-Induced Psychotic Disorder, Sedative-, Hypnotic-, or Anxiolytic- Induced Mood Disorder, Sedative-, Hypnotic-, or Anxiolytic-Induced Anxiety Disorder Sedative-, Hypnotic-, or Anxiolytic-Induced Sexual Dysfunction, Sedative-, Hypnotic-, or Anxiolytic-Induced Sleep Disorder and Sedative-, Hypnotic-, or Anxiolytic-Related Disorder Not Otherwise Specified (292.9); Polysubstance-Related Disorder such as Polysubstance Dependence (304.80); and Other (or Unknown) Substance-Related Disorders such as Anabolic Steroids, Nitrate Inhalants and Nitrous Oxide.
The compounds of formula (I) are also of use in the treatment of sleep disorders including primary sleep disorders such as Dyssomnias such as Primary Insomnia (307.42), Primary Hypersomnia (307.44), Narcolepsy (347), Breathing-Related Sleep Disorders (780.59), Circadian Rhythm Sleep Disorder (307.45) and Dyssomnia Not Otherwise Specified (307.47); primary sleep disorders such as Parasomnias such as Nightmare Disorder (307.47), Sleep Terror Disorder (307.46), Sleepwalking Disorder (307.46) and Parasomnia Not Otherwise Specified (307.47); Sleep Disorders Related to Another Mental Disorder such as Insomnia Related to Another Mental Disorder (307.42) and Hypersomnia Related to Another Mental Disorder (307.44); Sleep Disorder Due to a General Medical Condition; and Substance-Induced Sleep Disorder including the subtypes Insomnia Type, Hypersomnia Type, Parasomnia Type and Mixed Type.
The compounds of formula (I) are also of use in the treatment of eating disorders such as Anorexia Nervosa (307.1 ) including the subtypes Restricting Type and Binge- Eating/Purging Type; Bulimia Nervosa (307.51 ) including the subtypes Purging Type and Nonpurging Type; Obesity; Compulsive Eating Disorder; and Eating Disorder Not Otherwise Specified (307.50).
The compounds of formula (I) are also of use in the treatment of Autistic Disorder (299.00); Attention-Deficit /Hyperactivity Disorder including the subtypes Attention-Deficit /Hyperactivity Disorder Combined Type (314.01), Attention-Deficit /Hyperactivity Disorder Predominantly Inattentive Type (314.00), Attention-Deficit /Hyperactivity Disorder Hyperactive-Impulse Type (314.01 ) and Attention-Deficit /Hyperactivity Disorder Not Otherwise Specified (314.9); Hyperkinetic Disorder; Disruptive Behaviour Disorders such as Conduct Disorder including the subtypes childhood-onset type (321.81), Adolescent- Onset Type (312.82) and Unspecified Onset (312.89), Oppositional Defiant Disorder (313.81) and Disruptive Behaviour Disorder Not Otherwise Specified; and Tic Disorders such as Tourette's Disorder (307.23).
The compounds of formula (I) are also of use in the treatment of Personality Disorders including the subtypes Paranoid Personality Disorder (301.0), Schizoid Personality Disorder (301.20), Schizotypal Personality Disorder (301 ,22), Antisocial Personality Disorder (301.7), Borderline Personality Disorder (301 ,83), Histrionic Personality Disorder (301.50), Narcissistic Personality Disorder (301,81), Avoidant Personality Disorder (301.82), Dependent Personality Disorder. (301.6), Obsessive-Compulsive Personality Disorder (301.4) and Personality Disorder Not Otherwise Specified (301.9).
The compounds of Formula (I) are also of use in the enhancement of cognition including the treatment of cognition impairment in other diseases such as schizophrenia, bipolar disorder, depression, other psychiatric disorders and psychotic conditions associated with cognitive impairment. Within the context of the present invention, the term cognitive impairment includes for example the treatment of impairment of cognitive functions including attention, orientation, learning disorders, memory (i.e. memory disorders, amnesia, amnesic disorders, transient global amnesia syndrome and age-associated memory impairment) and language function; cognitive impairment as a result of stroke, Alzheimer's disease, Huntington's disease, Pick disease, Aids-related dementia or other dementia states such as Multiinfarct dementia, alcoholic dementia, hypotiroidism-related dementia, and dementia associated to other degenerative disorders such as cerebellar atrophy and amyotropic lateral sclerosis; other acute or sub-acute conditions that may cause cognitive decline such as delirium or depression (pseudodementia states) trauma, head trauma, age related cognitive decline, stroke, neurodegeneration, drug-induced states, neurotoxic agents, mild cognitive impairment, age related cognitive impairment, autism related cognitive impairment, Down's syndrome, cognitive deficit related to psychosis, and post-electroconvulsive treatment related cognitive disorders; and dyskinetic disorders such as Parkinson's disease, neuroleptic-induced parkinsonism, and tardive dyskinesias.
The compounds of formula (I) are also of use in the treatment of sexual dysfunctions including Sexual Desire Disorders such as Hypoactive Sexual Desire Disorder (302.71), and Sexual Aversion Disorder (302.79); sexual arousal disorders such as Female Sexual Arousal Disorder (302.72) and Male Erectile Disorder (302.72); orgasmic disorders such as Female Orgasmic Disorder (302.73), Male Orgasmic Disorder (302.74) and Premature Ejaculation (302.75); sexual pain disorder such as Dyspareunia (302.76) and Vaginismus (306.51); Sexual Dysfunction Not Otherwise Specified (302.70); paraphilias such as Exhibitionism (302.4), Fetishism (302.81), Frotteurism (302.89), Pedophilia (302.2), Sexual Masochism (302.83), Sexual Sadism (302.84), Transvestic Fetishism (302.3), - Voyeurism (302.82) and Paraphilia Not Otherwise Specified (302.9); gender identity disorders such as Gender Identity Disorder in Children (302.6) and Gender Identity Disorder in Adolescents or Adults (302.85); and Sexual Disorder Not Otherwise Specified (302.9).
The invention also provides a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of schizophrenia, mood disorders, anxiety disorders, substance-related disorders, sleep disorders, eating disorders, autistic disorder, attention-deficit/hyperactivity disorder, disruptive behaviour disorder, tic disorders, personality disorders, cognition impairment in other diseases, sexual dysfunction, Parkinson's disease, dyskinetic disorders, depression, bipolar disorder, cognitive impairment, obesity, emesis, movement disorders, obsessive- compulsive disorders, amnesia, aggression, vertigo, dementia and circadian rhythm disorders.
The invention also provides a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of psychotic disorders, schizophrenia, Parkinson's disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders.
In another aspect of the invention, there is provided a method of treating a mammal, including a human, suffering from or susceptible to a disorder mediated by GlyTI , which comprises administering an effective amount of a compound of formula (I) as hereinbefore defined or a salt or solvate thereof.
The invention also provides a method of treating schizophrenia, mood disorders, anxiety disorders, substance-related disorders, sleep disorders, eating disorders, autistic disorder, attention-deficit/hyperactivity disorder, disruptive behaviour disorder, tic disorders, personality disorders, cognition impairment in other diseases, sexual dysfunction, Parkinson's disease, dyskinetic disorders, depression, bipolar disorder, cognitive impairment, obesity, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, vertigo, dementia and circadian rhythm disorders which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof.
The invention also provides a method of treating psychotic disorders, schizophrenia, Parkinson's disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof.
In another aspect of the invention, there is provided use of a compound of formula (I) as hereinbefore defined or a salt or solvate thereof in the preparation of a medicament for the treatment of a disorder mediated by GlyTI .
Preferably, the disorder mediated by GlyTI to be treated by the use or method as hereinbefore described is a psychosis, including schizophrenia, dementia and attention deficit disorders, particularly schizophrenia.
The invention also provides the use of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of schizophrenia, mood disorders, anxiety disorders, substance-related disorders, sleep disorders, eating disorders, autistic disorder, attention- deficit/hyperactivity disorder, disruptive behaviour disorder, tic disorders, personality disorders, cognition impairment in other diseases, sexual dysfunction, Parkinson's disease, dyskinetic disorders, depression, bipolar disorder, cognitive impairment, obesity, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, vertigo, dementia and circadian rhythm disorders.
The invention also provides the use of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of psychotic disorders, schizophrenia, Parkinson's disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders.
As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
Compounds for use according to the invention may be administered as the raw material but the active ingredients are preferably provided in the form of pharmaceutical compositions.
Accordingly, in a further aspect of the invention, there is provided a pharmaceutical composition comprising a compound of formula (I) as hereinbefore described or a salt or solvate thereof, and at least one pharmaceutically acceptable carrier, diluent or excipient. These pharmaceutical compositions may be used in the treatment of clinical conditions for which a GlyTI inhibitor is indicated such as, for example, schizophrenia. The carrier must be pharmaceutically acceptable to the recipient and must be compatible with, i.e. not have a deleterious effect upon, the other ingredients in the composition. The carrier may be a solid or a liquid and is preferably formulated with at least one compound of formula (I) or a salt or solvate thereof as a unit dose formulation. If desired, other physiologically active ingredients may also be incorporated in the pharmaceutical compositions of the invention.
It will be appreciated by those skilled in the art that the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents such as 5HT3 antagonists, serotonin agonists, NK-1 antagonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants, dopaminergic antidepressants, H3 antagonists, 5HT1A antagonists, 5HT1B antagonists, 5HT1D antagonists, D1 agonists, M1 agonists and/or anticonvulsant agents, as well as atypical antipsychotic drugs and cognitive enhancers.
Suitable 5HT3 antagonists which may be used in combination of the compounds of the inventions include for example ondansetron, granisetron, metoclopramide.
Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.
Suitable SSRIs which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.
Suitable SNRIs which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.
Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptiline, chlomipramine and nortriptiline.
Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.
Suitable anticonvulsant agents which may be used in combination of the compounds of the invention include for example divalproex, carbamazepine and diazepam.
Suitable atypical antipsychotic drugs which which may be used in combination of the compounds of the invention include for example risperidone, olanzapine, ziprasidone, aripiprazole and clozapine. It will be appreciated that the compounds of the combination or composition may be administered simultaneously (either in the same or different pharmaceutical formulations), separately or sequentially.
The compounds of formula (I) and their pharmaceutically acceptable salts and solvates thereof are also suitable for combination with other typical and atypical antipsychotics to provide improved treatment of psychotic disorders. Particular advantages associated with the combinations, uses and methods of treatment of compounds of formula (I) and their pharmaceutically acceptable salts and solvates thereof include equivalent or improved efficacy at doses of administration which are lower than those commonly used for the individual components. Improved treatments of positive symptoms and/or negative symptoms and/or cognitive symptoms of the psychotic disorder may also be observed. The combinations, uses and methods of treatment of the invention may also provide advantages in treatment of patients who fail to respond adequately or who are resistant to treatment with certain neuroleptic agents.
The combination therapies of the invention are preferably administered adjunctively. By adjunctive administration is meant the coterminous or overlapping administration of each of the components in the form of separate pharmaceutical compositions or devices. This regime of therapeutic administration of two or more therapeutic agents is referred to generally by those skilled in the art and herein as adjunctive therapeutic administration; it is also known as add-on therapeutic administration. Any and all treatment regimes in which a patient receives separate but coterminous or overlapping therapeutic administration of the compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one neuroleptic agent are within the scope of .the current invention. In one embodiment of adjunctive therapeutic administration as described herein, a patient is typically stabilised on a therapeutic administration of one or more of the of the components for a period of time and then receives administration of another component. Within the scope of this invention, it is preferred that the compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof is administered as adjunctive therapeutic treatment to patients who are receiving administration of at least one neuroleptic agent, but the scope of the invention also includes the adjunctive therapeutic administration of at least one neuroleptic agent to patients who are receiving administration of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
The combination therapies of the invention may also be administered simultaneously. By simultaneous administration is meant a treatment regime wherein the individual components are administered together, either in the form of a single pharmaceutical composition or device comprising or containing both components, or as separate compositions or devices, each comprising one of the components, administered simultaneously. Such combinations of the separate individual components for simultaneous combination may be provided in the form of a kit-of-parts. In a further aspect therefore, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof to a patient receiving therapeutic administration of at least one neuroleptic agent. In a further aspect, the invention provides the use of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one neuroleptic agent. The invention further provides compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one neuroleptic agent.
In a further aspect, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of at least one neuroleptic agent to a patient receiving therapeutic administration of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof. In a further aspect, the invention provides the use of at least one neuroleptic agent in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof. The invention further provides at least one neuroleptic agent for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
In a further aspect, the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof in combination with at least one neuroleptic agent. The invention further provides the use of a combination of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one neuroleptic agent in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a psychotic disorder. The invention further provides the use of compounds of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for simultaneous therapeutic administration with at least one neuroleptic agent in the treatment of a psychotic disorder. The invention further provides compounds of formula (I) or a pharmaceutically acceptable salt thereof for use for simultaneous therapeutic administration with at least one neuroleptic agent in the treatment of a psychotic disorder. The invention further provides the use of at least one neuroleptic agent in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) or a pharmaceutically acceptable salt thereof in the treatment of a psychotic disorder. In further aspects, the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of a pharmaceutical composition comprising compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one mood stabilising or antimanic agent, a pharmaceutical composition comprising compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one mood stabilising or antimanic agent, the use of a pharmaceutical composition comprising compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one mood stabilising or antimanic agent in the manufacture of a medicament for the treatment of a psychotic disorder, and a pharmaceutical composition comprising compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one mood stabilising or antimanic agent for use in the treatment of a psychotic disorder.
In a further aspect, the invention provides a kit-of-parts for use in the treatment of a psychotic disorder comprising a first dosage form comprising compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof and one or more further dosage forms each comprising a neuroleptic agent for simultaneous therapeutic administration.
Within the context of the present invention, the term psychotic disorder includes those disorders mentioned above, such as schizophrenia, mood disorders, anxiety disorders, substance-related disorders, sleep disorders, eating disorders, autistic disorder, attention- deficit/hyperactivity disorder, disruptive behaviour disorder, tic disorders, personality disorders, cognition impairment in other diseases, sexual dysfunction, dyskinetic disorders, depression, bipolar disorder, cognitive impairment and obsessive-compulsive disorders and all the various forms of the disorders as mentioned herein.- which are contemplated as part of the present invention.
Examples of neuroleptic/antipsychotic drugs that are useful in the present invention include, but are not limited to: butyrophenones, such as haloperidol, pimozide, and droperidol; phenothiazines, such as chlorpromazine, thioridazine, mesoridazine, trifluoperazine, perphenazine, fluphenazine, thiflupromazine, prochlorperazine, and acetophenazine; thioxanthenes, such as thiothixene and chlorprothixene thienobenzodiazepines; dibenzodiazepines; benzisoxazoles; dibenzothiazepines imidazolidinones ; benzisothiazolyl-piperazines; triazine such as lamotrigine dibenzoxazepines, such as loxapine; dihydroindolones, such as molindone; aripiprazole and derivatives thereof that have antipsychotic activity.
Examples of neuroleptic drugs that are preferred for use in the present invention are shown in Table 1.
Table 1 Neuroleptic drugs
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Examples of tradenames and suppliers of selected neuroleptic drugs are as follows : clozapine (available under the tradename CLOZARIL®, from Mylan, Zenith Goldline, UDL, Novartis); olanzapine (available under the tradename ZYPREX®, from Lilly ; ziprasidone (available under the tradename GEODON®, from Pfizer); risperidone (available under the tradename RISPERDAL®, from Janssen); quetiapine fumarate (available under the tradename SEROQUEL®, from AstraZeneca); haloperidol (available under the tradename HALDOL®, from Ortho-McNeil); chlorpromazine (available under the tradename THORAZINE®, from SmithKline Beecham (GSK); fluphenazine (available under the tradename PROLIXIN®, from Apothecon, Copley, Schering, Teva, and American Pharmaceutical Partners, Pasadena); thiothixene (available under the tradename NAVANE®;, from Pfizer); trifluoperazine (10-[3-(4-methyI-1-piperazinyl)propyl]- 2-(trifluoromethyl)phenothiazine dihydrochloride, available under the tradename STELAZINE®, from Smith Klein Beckman; perphenazine (available under the tradename TRILAFON®; from Schering); thioridazine (available under the tradename MELLARIL®; from Novartis, Roxane, HiTech, Teva, and Alpharma) ; molindone (available under the tradename MOBAN®, from Endo); and loxapine (available under the tradename LOXITANE®; from Watson). Furthermore, benperidol (Glianimon®), perazine (Taxilan®) or melperone (Eunerpan®)) may be used.
Other preferred neuroleptic drugs include promazine (available under the tradename SPARINE®), triflurpromazine (available under the tradename VESPRIN®), chlorprothixene (available under the tradename TARACTAN®), droperidol (available under the tradename INAPSINE®), acetophenazine (available under the tradename TINDAL®;), prochlorperazine (available under the tradename COMPAZINE®), methotrimeprazine (available under the tradename NOZINAN®), pipotiazine (available under the tradename PIPOTRIL®), ziprasidone, and hoperidone.
Particularly preferred neuroleptic agents for use in the invention are olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant.
Possible formulations include those suitable for oral, sub-lingual, buccal, parenteral (for example, subcutaneous, intramuscular, or intravenous), rectal, topical and intranasal administration and in forms suitable for administration by inhalation or insufflation (either through the mouth or nose). The most suitable means of administration for a particular patient will depend on the nature and severity of the conditions being treated and on the nature of the active compound, but, where possible, oral administration is preferred.
Formulations suitable for oral administration may be provided as discrete units, such as tablets, capsules, cachets, or lozenges, each containing a predetermined amount of the active compound; as powders or granules; as solutions or suspensions in aqueous or non-aqueous liquids; or as oil-in-water or water-in-oil emulsions. Formulations suitable for sublingual or buccal administration include lozenges comprising the active compound and, typically, a flavoured base, such as sugar and acacia or tragacanth and pastilles comprising the active compound in an inert base, such as gelatin and glycerin or sucrose and acacia.
Formulations suitable for parenteral administration typically comprise sterile aqueous solutions containing a predetermined concentration of the active compound; the solution is preferably isotonic with the blood of the intended recipient. Although such solutions are preferably administered intraveneously, they may also be administered by subcutaneous or intramuscular injection.
Formulations suitable for rectal administration are preferably provided as unit-dose suppositories comprising the active ingredient and one or more solid carriers forming the suppository base, for example, cocoa butter.
Formulations suitable for topical or intranasal application include ointments, creams, lotions, pastes, gels, sprays, aerosols and oils. Suitable carriers for such formulations include petroleum jelly, lanolin, polyethylene glycols, alcohols, and combinations thereof.
The formulations of the invention may be prepared by any suitable method, typically by uniformly and intimately admixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions and then, if necessary, shaping the resulting mixture into the desired shape.
For example, a tablet may be prepared by compressing an intimate mixture comprising a powder or granules of the active ingredient and one or more optional ingredients, such as a binder, lubricant, inert diluent, or surface active dispersing agent, or by moulding an intimate mixture of powdered active ingredient and inert liquid diluent.
Aqueous solutions for parenteral administration are typically prepared by dissolving the active compound in sufficient water to give the desired concentration and then rendering the resulting solution sterile and isotonic.
It will be appreciated that reference to treatment is intended to include prophylaxis as well as the alleviation of established symptoms.
It will be appreciated that the precise dose administered will depend on the age and condition of the patient and the frequency and route of administration and will be at the ultimate discretion of the attendant physician. The compound may be administered in single or divided doses and may be administered one or more times, for example 1 to 4 times per day. A proposed dose of the active ingredient for use according to the invention for oral, sub- lingual, parenteral, buccal, rectal, intranasal or topical administration to a human (of approximately 70 kg bodyweight) for the treatment of neurological and neuropsychiatric disorders mediated by a GlyTI inhibitor, including schizophrenia, may be about 1 to about 1000 mg, preferably about 5 to about 500 mg, more preferably about 10 to about 100 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
The invention is further illustrated by the following non-limiting examples. Examples
As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. Specifically, the following abbreviations may be used in the examples and throughout the specification:
g (grams); mg (milligrams);
L (litres); ml (millilitres); μL (microlitres); psi (pounds per square inch);
M (molar); mM (millimolar); i. v. (intravenous); Hz (Hertz);
MHz (megahertz); mol (moles); mmol (millimoles); RT (room temperature); min (minutes); h (hours); mp (melting point); TLC (thin layer chromatography);
Tr (retention time); RP (reverse phase);
MeOH (methariol); /-PrOH (isopropanol);
TEA (triethylamine); TFA (trifluoroacetic acid);
TFAA (trifluoroacetic anhydride); THF (tetrahydrofuran);
DMSO (dimethylsulfoxide); EtOAc (ethyl acetate);
DME (1 ,2-dimethoxyethane); DCM (dichloromethane);
DCE (dichloroethane); DMF (N./V-dimethylformamide); DMPU (Λ/,Λ/'-dimethyIpropyleneurea); (GDI (1 ,1-carbonyldiimidazole); IBCF (isobutyl chloroformate); HOAc (acetic acid);
HOSu (Λ/-hydroxysuccinimide); HOBT (1-hydroxybenzotriazole); mCPBA (meta-chloroperbenzoic acid; EDC (ethylcarbodiimide hydrochloride); BOC (ife/ -butyloxycarbonyl); FMOC (9-fluorenylmethoxycarbonyl);
DCC (dicyclohexylcarbodiimide); CBZ (benzyloxycarbonyl);
Ac (acetyl); atm (atmosphere);
TMSE (2-(trimethylsilyl)ethyl); TMS (trimethylsilyl);
TIPS (triisopropylsilyl); TBS (f-butyldimethylsilyl); Me (methyl); HPLC (high pressure liquid chromatography);
Et (ethyl); tBu (tert-butyl).
All references to ether are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in °C (degrees Centigrade). All reactions conducted under an inert atmosphere at room temperature unless otherwise noted.
1H NMR spectra were recorded on a Bruker B-ACS 60 400MHz, Bruker DPX 400 or a
Bruker DPX 250. Chemical shifts are expressed in parts per million (ppm, δ units). Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q (quartet), dd
(double doublet), dt (double triplet), m (multiplet), br (broad).
Low-resolution mass spectra (MS) were recorded on a HP1100 series spectrometer; MS and liquid chromatography MS were recorded on a Micromass MS2 Platform LC spectrometer. All mass spectra were taken under electrospray ionisation (ESI), chemical ionisation (Cl), electron impact (El) or by fast atom bombardment (FAB) methods. All reactions were monitored by thin-layer chromatography on 0.25 mm E. Merck silica gel plates (60F-254), visualised with UV light, 5% ethanolic phosphomolybdic acid or p- anisaldehyde solution. Flash column chromatography was performed on silica gel (230- 400 mesh, Merck).
The following descriptions set out the syntheses of intermediates particularly useful in the synthesis of compounds of formulae (I) and (la).
Description 1
General description exemplified for (R)-1-azido-3-pyrrolidin-1-ylpropan-2-ol (D1).
Figure imgf000039_0001
The title compound was prepared using the method of Dhanoa et al, Tet. Lett., 33 (13) p.1725-8, (1992). Pyrrolidine (0.41ml; 5mmol) was added to a suspension of potassium hydride (35% in mineral oil) (630mg; 5.5mmol) in anhydrous tetrahydrofuran (THF) (20ml) under argon. After stirring for 2h, a solution of (S)-(+)-glycidyl nosylate (1.19g; 4.6mmol) in anhydrous THF (5ml) was added over 2 minutes. The mixture was stirred overnight at ambient temperature, then filtered through kieselguhr and washed with THF. Finally, the mixture was concentrated under reduced pressure to approximately a quarter of the original volume (n.b. use cold water bath - volatile product). The resulting THF solution of crude epoxide was treated with lithium azide (20% solution in water) (5 eq; 6.2ml) then heated at 70° overnight. The cooled solution was evaporated under reduced pressure and the residue treated with saturated aqueous NaHCO3 solution and extracted into ethyl acetate (x 2). The organic phase was dried (Na2SO4) and evaporated under reduced pressure to a light brown oil. Purified by column chromatography, eluting with methanol/dichloromethane (2.5%, 4%) to afford the pure hydroxy azide as a pale orange oil (168mg, 21% over two steps). MH+ 171.
Description 2
General description exemplified for (S)-1-amino-3-pyrrolidin-1-ylpropan-2-oI (D2)
Figure imgf000040_0001
A solution of (R)-1-azido-3-pyrrolidin-1-ylpropan-2-ol (D1) (168mg; 0.988mmol) in methanol (10ml) was hydrogenated at atmospheric pressure and ambient temperature over Pearlmans' catalyst (130mg) overnight. The catalyst was removed by filtration through kieselguhr, and the filtrate evaporated under reduced pressure, to yield the title compound as a clear colourless oil (130mg; 91%).
Description 3
(R)-1-Azido-3-(2-methylpyrrolidin-1-yl)propan-2-ol (D3)
Figure imgf000040_0002
The title compound was prepared from 2-methylpyrrolidine (430mg; 5.06mmol) using the method outlined in Description 1 (119mg; 14% over 2 steps). MH+ 185. 1H NMR (400MHz, CDCI3) δ: 3.86-3.78 (m,1H), 3.4-3.31 (m,1H), 3.29-3.13 (m,2H), 3.03-2.57 (m,2H), 2.53-2.42 (m,1H), 2.2-2.11 (m,1H), 1.98-1.89 (m,1H), 1.83-1.67 (m,2H), 1.45-1.35 (m,1 H), 1.09 (t,3H).
Description 4
(S)-1 -Amino-3-(2-methylpyrrolidin-1 -yl)propan-2-ol (D4).
Figure imgf000040_0003
The title compound was obtained from (R)-1-azido-3-(2-methylpyrrolidin-1-yl)propan-2-ol (D3) (119mg; 0.646mmol) using the method outlined in Description 2 (80mg; 78%) MH+ 159.
Description 5
2,4-Dimethylpyrrolidine (D5)
Figure imgf000041_0001
The title compound was prepared by the method of DeJong and Wibaut, Reel. Trav. Chim. Pays-Bas., 49 p.237-46 (1930). A solution of 2,4-dimethylpyrroie (10g; 0.105mol) in glacial acetic acid (500ml) was hydrogenated at atmospheric pressure and ambient temperature over platinum oxide (2g). After 4h, a further 2g platinum oxide was added and the reaction continued overnight. The catalyst was removed by filtration, and the resulting filtrate was basified strongly with potassium hydroxide pellets (with addition of ice and external card-ice/acetone cooling). The product was obtained by steam distillation of the basic solution, followed by extraction with diethyl ether. The organic phase was dried (Na2SO4) and evaporated under reduced pressure (n.b. use cold water bath - volatile product) to leave the crude product which was further purified by bulb-to-bulb distillation as a clear, colourless oil. (5g; 48%). 1H NMR (400MHz, CDCI3) δ: 3.2-3.1 (m,1H), 3.05- 2.99 (m, 1H), 2.56-2.5 (m, 1H), 2.22-2.13 (m, 1H), 2.11-2.03 (m,1H), 1.15 (d,3H), 1.00 (d,3H), 0.88-0.79 (m,1H).
Description 6:
(R)-1 -Azido-3-(2,4-dimethylpyrrolidin-1 -yl)propan-2-ol (D6)
Figure imgf000041_0002
The title compound was prepared from 2,4-dimethylpyrrolidine (D5) (193mg;1.94mmol) using the method outlined in Description 1 (91 mg; 26% over 2 steps) MH+ 199.
Description 7:
(S)-1 -Amino-3-(2,4-dimethylpyrrolidin-1 -yl)propan-2-oI (D7)
Figure imgf000042_0001
The title compound was prepared from (R)-1-azido-3-(2,4-dimethylpyrrolidin-1-yI)propan- 2-ol (D6) (91 mg, 0.459mmol) using the method outlined in Description 2 (69mg; 87%). MH+ 173.
Description 8
(R)-1-Azido-3-(2-isopropylpyrrolidin-1-yl)propan-2-ol (D8)
Figure imgf000042_0002
The title compound was prepared from 2-isopropylpyrrolidine (565mg; 5mmol) using the method outlined in Description 1 (379mg; 39% over 2 steps). MH+ 213.
Description 9
(S)-1 -Amino-3-(2-isopropylpyrrolidin-1 -yl)propan-2-ol (D9)
Figure imgf000042_0003
The title compound was prepared from (R)-1-azido-3-(2-isopropylpyrrolidin-1-yl)propan-2- ol (D8) (379mg; 1.78mmol) using the method outlined in Description 2 (303mg; 91%).
Description 10
(R)-1-Azido-3-(2,5-dimethylpyrrolidin-1 -yl)-propan-2-ol (D10)
Figure imgf000042_0004
The title compound was prepared from 2,5-dimethylpyrrolidine (495mg; 5mmol) using the method outlined in Description 1 (185mg; 20% over 2 steps). MH+ 199.
Description 11
(S)-1-Amino-3-(2,5-dimethylpyrrolidin-1-yl)-propan-2-ol (D11)
Figure imgf000043_0001
The title compound was prepared from (R)-1-azido-3-(2,5-dimethylpyrrolidin-1-yI)-propan- 2-ol (D10) (185mg; 0.93mmol) using the method outlined in Description 2 (145mg; 90%).
Description 12
(R)-1-Azido-3-(2-cyclohexylpyrrolidin-1-yl)propan-2-ol (D12)
Figure imgf000043_0002
The title compound was prepared from 2-cyclohexylpyrrolidine (1.0g; 6.54mmol) using the method outlined in Description 1 (220mg; 15% over 2 steps). MH+ 253.
Description 13
(S)-1-Amino-3-(2-cyclohexylpyrrolidin-1-yl)propan-2-ol (D13)
Figure imgf000043_0003
The title compound was prepared from (R)-1-azido-3-(2-cyclohexylpyrrolidin-1-yl)propan- 2-ol (D"12) (220mg; 0.873mmol) using the method outlined in Description 2 (177mg; 90%). MH+ 227.
Description 14 (R)-1-Azido-3-(2-isobutyIpyrrolidin-1-yI)propan-2-ol (D14)
Figure imgf000044_0001
The title compound was prepared from 2-isobutylpyrrolidine (700mg; 5.5mmol) using the method outlined in Description 1 (369mg; 33% over 2 steps). MH+ 227.
Description 15
(S)-1-Amino-3-(2-isobutylpyrrolidin-1-yl)propan-2-ol (D15)
Figure imgf000044_0002
The title compound was prepared from (R)-1-azido-3-(2-isobutylpyrrolidin-1-yl)propan-2-ol (D14) (369mg; 1.6mmol) using the method outlined in Description 2 (302mg; 92%). MH+ 201.
Description 16
2-Ethylpyrrolidine (D16)
Figure imgf000044_0003
The title compound was prepared from 2-ethyl pyrrole (2.0g; 0.021 mol) using the method outlined in Description 5 (525mg; 25%). MH+ 100.
Description 17
(R)-1-Azido-3-(2-ethylpyrrolidin-1-yl)propan-2-ol (D17)
Figure imgf000045_0001
The title compound was prepared from 2-ethylpyrrolidine (D16) (525mg; 5.3mmol) using the method outlined in Description 1 (82mg; 8% over 2 steps).
Description 18
(S)-1-Amino-3-(2-ethylpyrrolidin-1-yl)propan-2-ol (D18)
Figure imgf000045_0002
The title compound was prepared from (R)-1-azido-3-(2-ethylpyrrolidin-1-yl)propan-2-ol (D17) (82mg; 0.414mmol) using the method outlined in Description 2 (65mg; 91%).
Description 19
2-fe/ -Butylpyrrolidine hydrochloride (D19)
Figure imgf000045_0003
To a solution of 5-ferf-butyl-3,4-dihydro-2H-pyrrole (prepared from 2-pyrrolidone using the method of Mundy et al, J.Org. Chem., 39, (13) p.1963, 1974) (200mg; 1.6mmol) in methanol (10ml) was added sodium borohydride portionwise (121mg; 3.2mmol) and the solution was stirred at ambient temperature for 2h. 1.0M ethereal HCI (5ml) was added portionwise, and the mixture was stirred for 1hr. The white precipitate was removed by filtration and the organic phase was evaporated under reduced pressure, to afford the title compound as a white powder (128mg; 49%). MH+ 128. 1H NMR (400MHz, d4-MeOH) δ: 3.35-3.2 (m,3H), 2.12-1.95 (m, 3H), 1.83-1.72 (m,1H), 1.04 (s, 9H).
Description 20
(R)-1-Azido-3-(2-terf-butylpyrrolidin-1-yl)propan-2-ol (D20)
The title compound was prepared from 2-ferf-butylpyrrolidine hydrochloride (D19) (817mg, 5mmoI) using the method outlined in Description 1, (n.b. 2.6 equivalents of potassium hydride used) (282mg; 27% over 2 steps). MH+ 227.
Description 21
(S)-1-Amino-3-(2-ferf-butylpyrrolidin-1-yl)propan-2-ol (D21 )
Figure imgf000046_0002
The title compound was prepared from (R)-1-azido-3-(2-tett-butylpyrrolidin-1-yI)propan-2- ol (D20) (282mg; 1.25mmol) using the method outlined in description 2 (112mg; 45%). MH+ 201.
Description 22
2-cyclopropylpyrroIidine hydrochloride (D22)
Figure imgf000046_0003
The title compound was prepared from 5-cyclopropyl-3,4-dihydro-2 - -pyrrole (prepared from 2-pyrrolidone using the method of Mundy et al, J.Org. Chem., 39, (13) p.1963, 1974) (1.4g; 12.8mmol) using the method outlined in Description 19 (1.54g; 81%). MH+ 112.
Description 23
(R)-1-Azido-3-(2-cyclopropylpyrrolidin-1-yl)propan-2-ol (D23)
Figure imgf000047_0001
The title compound was prepared from 2-cyclopropylpyrrolidine hydrochloride (D22) (1.54g; 0.01 mol) using the method outlined in Description 1 (n.b. 2.6 equivalents of potassium hydride used) (420mg; 21 % over 2 steps). MH+ 211.
Description 24
(S)-1-Amino-3-(2-cyclopropylpyrrolidin-1-yl)propan-2-ol (D24)
Figure imgf000047_0002
The title compound was prepared from (R)-1-azido-3-(2-cyclopropylpyrrolidin-1-yl)propan- 2-o! (D23) (420mg; 20mmol) using the method outlined in Description 2 (336mg; 91%). MH+ 185.
Description 25
(R)-1-Azido-3-(3-methyIpiperidin-1-yl)propan-2-ol (D25)
Figure imgf000047_0003
The title compound was prepared from 3-methylpiperidine (0.5g; 5mmol) using the method outlined in Description 1 (404mg; 44% over 2 steps). MH+ 199.
Description 26
(S)-1 -Amino-3-(3-methylpiperidin-1 -yl)propan-2-ol (D26)
Figure imgf000047_0004
The title compound was prepared from (R)-1-azido-3-(3-methylpiperidin-1-yl)propan-2-ol (D25) (404mg; 2.04mmol) using the method outlined in Description 2 (310mg; 88%). MH+ 173. Description 27
(R)-1-Azido-3-(5-ethyl-2-methylpiperidin-1-y|)propan-2-ol (D27)
Figure imgf000048_0001
The title compound was prepared from 5-ethyl-2-methylpiperidine (635mg; 5mmol) using the method outlined in Description 1 (244mg; 23% over 2 steps). MH+ 227.
Description 28
(S)-1-Amino-3-(5-ethyl-2-methylpiperidin-1-yl)propan-2-ol (D28)
Figure imgf000048_0002
The title compound was prepared from (R)-1-azido-3-(5-ethyl-2-methylpiperidin-1- yl)propan-2-ol (D27) (244mg; 0.108mmol) using the method outlined in Description 2 (140mg; 65%).
Description 29
(R)-1 -Azido-3-(2-ethylpiperidin-1 -yl)propan-2-ol (D29)
Figure imgf000048_0003
The title compound was prepared from 2-ethylpiperidine (0.67ml; 5.05mmol) using the method outlined in Description 1 (255mg; 26% over 2 steps). MH+ 213.
Description 30
(S)-1-Amino-3-(2-ethylpiperidin-1-yl)propan-2-ol (D30)
Figure imgf000048_0004
The title compound was prepared from (R)-1-azido-3-(2-ethylpiperidin-1-yl)propan-2-ol (D29) (255mg; 1.2mmol) using the method outlined in Description 2 (188mg; 84%). MH+ 187.
Description 31
2-lsopropylpiperidine (D31)
Figure imgf000049_0001
The title compound was prepared from 2-isopropylpyridine (10g; 0.083mo!) using the method outlined in Description 5 (7.3g; 70%). MH+ 128.
Description 32
(R)-1-Azido-3-(2-isopropylpiperidin-1-yl)propan-2-ol (D32)
Figure imgf000049_0002
The title compound was prepared from 2-lsopropylpiperidine (D31) (641 mg; 5.05mmol) using the method outlined in Description 1 (80mg; 8% over 2 steps). MH+ 227.
Description 33
(S)-1-Amino-3-(2-isopropylpiperidin-1-yl)propan-2-ol (D33)
Figure imgf000049_0003
The title compound was prepared from (R)-1-azido-3-(2-isopropylpiperidin-1-yl)propan-2- ol (D32) (80mg; 0.353mmol) using the method outlined in Description 2 (50mg; 71%). Description 34
(R)-Azido-(sec-butylpropylamino)propan-2-ol (D34)
Figure imgf000050_0001
The title compound was prepared from N-n-propyl-N-sec-butylamine (575mg; 5mmol) using the method outlined in Description 1 (133mg; 14% over 2 steps). MH+ 215.
Description 35
(S)-Amino-(sec-butylpropylamino)propan-2-ol (D35)
Figure imgf000050_0002
The title compound was prepared from (R)-azido-(seobutylpropylamino)propan-2-ol (D34) (133mg; 0.62mmol) using the method outlined in Description 2 (79mg; 68%). MH+ 189.
Description 36
tert-butylpropylamine (D36)
Figure imgf000050_0003
A solution of te/ϊ-butylamine 12.28g; 0.168mol) and n-propyl bromide (10.34g; 0.084mol) in N,N-dimethylformamide (30ml) was heated at gentle reflux overnight. On cooling, the crude product crystallised as the hydrobromide salt, and was was triturated with diethyl ether and filtered, to give a white crystalline solid. (11.45g; 70%). The salt was free-based by dissolving in 15% aq. sodium hydroxide solution, and removing the upper oily layer. Bulb-to-bulb distillation gave the pure product as a colourless oil. 1H NMR (400MHz, d4- MeOH) δ: 2.49 (t, 2H), 1.53-1.42 (m,2H), 1.1 (s,9H), 0.95 (t,3H).
Description 37
(R)-Azido-(te/τf-butylpropylamino)propan-2-ol (D37)
Figure imgf000051_0001
The title compound was prepared from fert-butylpropylamine (D36) (632mg; 5.5mmol) using the method outlined in Description 1 (40mg; 4% over 2 steps).
Description 38
(S)-Amino-(ferf-butylpropylamino)propan-2-ol (D38)
Figure imgf000051_0002
The title compound was prepared from (R)-azido-(fe/f-butyIpropylamino)propan-2-ol (D37) (40mg; 0.187mmol) using the method outlined in Description 2 (32mg; 91%). MH+ 189.
Description 39
(R)-1-Azido-3-(1 ,3-dihydroisoindol-2-yl)propan-2-oI (D39)
Figure imgf000051_0003
The title compound was prepared from 2,3-dihydro-1H-isoindole (595mg;5mmol) using the method outlined in Description 1 (484mg; 48% over 2 steps). MH+ 219.
Description 40
(S)-1 -Amino-3-(1 ,3-dihydroisoindol-2-yl)propan-2-ol (D40)
Figure imgf000051_0004
The title compound was prepared from (R)-1-azido-3-(1,3-dihydroisoindol-2-yl)propan-2-ol (D39) "(484mg; 2.2mmol) using the method outlined in Description 2 (396mg; 93%). MH+ 193. Description 41
(R)-1-Azido-3-(octahydroisoquinolin-1-yl)propan-2-ol (D41 )
Figure imgf000052_0001
The title compound was prepared from decahydroisoquinoline (695mg; 5mmoI) using the method outlined in Description 1 (336mg; 31% over 2 steps). MH+ 239.
Description 42
(S)-1-Amino-3-(octahydroisoquinolin-1-yl)propan-2-ol (D42)
Figure imgf000052_0002
The title compound was prepared from (R)-1-azido-3-(octahydroisoquinoIin-1-yl)propan-2- ol (D41) (336mg; 1.41 mmol) using the method outlined in Description 2 (267mg; 89%). MH+ 213.
Description 43
(R)-1-Azido-3-(octahydroquinolin-1-yl)propan-2-ol (D43)
Figure imgf000052_0003
The title compound was prepared from decahydroquinoline (910mg; 6.54mmol) using the method outlined in Description 1 (346mg; 25% over 2 steps). MH+ 239.
Description 44
(S)-1-Amino-3-(octahydroquinolin-1-yl)propan-2-ol (D44)
Figure imgf000053_0001
The title compound was prepared from (R)-1-azido-3-(octahydroquinolin-1-yl)propan-2-ol (D43) (346mg; 1.45mmol) using the method outlined in Description 2 (288mg; 93%). MH+ 213.
Description 45
(R)-1-Azido-3-((1S,5R)-1 ,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)propan-2-ol (D45)
Figure imgf000053_0002
The title compound was prepared from (1S,5R)-1 ,3,3-trimethyl-6-azabicyclo[3.2.1]octane (0.857ml; 5.05mmol) using the method outlined in Description 1 (213mg; 18% over 2 steps). MH+ 253.
Description 46
(S)-1-Amino-3-((1 S,5R)-1 ,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)propan-2-ol (D46)
Figure imgf000053_0003
The title compound was prepared from (R)-1-azido-3-((1S,5R)-1 ,3,3-trimethyl-6- azabicyclo[3.2.1]oct-6-yl)propan-2-ol (D45) (213mg; 0.845mmol) using the method outlined in Description 2 (153mg; 80%). MH+ 227.
Descrrption 47
(R)-1-Amino-3-(2,4-dimethylpyrrolidin-1-yl)propan-2-ol (D47)
Figure imgf000054_0001
The title compound was prepared from 2,4-dimethylpyrrolidine (193mg;1.94mmol) and (R)-(-)-gIycidyl nosylate (460mg; 1.77mmol) using the methods outlined in Descriptions 1 and 2 (71 mg; 23% over three steps). MH+ 173.
Description 48
1 -(R)-1 -Oxiranylmethyl-piperidine (D48)
Figure imgf000054_0002
Potassium hydride (527mg; 30% in oil) was weighed into an oven-dried 3-necked flask and THF (5ml) was added under an atmosphere of argon. A solution of piperidine (0.44ml) in THF (5ml) was added to the stirred suspension. The reagents were stirred together at room temperature for 2 hrs, under an atmosphere of argon. S-(-)-Glycidyl nosylate (904mg) was then added dropwise as a solution in THF (5ml) and the reaction mixture stirred at room temperature overnight. The reaction mixture was filtered under an inert atmosphere through Celite™ and the liquor reduced to half volume in vacuo, m/z (API+) 142 [MH+].
Description 49
(R)-1-Azido-3-piperidin-1-yl-propan-2-ol (D49)
Figure imgf000054_0003
To the product solution from Description 48 was added lithium azide (5.34ml; 20% solution in water) and the reaction mixture heated at 70°C overnight. The THF was then removed in vacuo and the solution partitioned between EtOAc and NaHCO3 solution. Organics were collected, dried (MgSO4), and evaporated. The residual oil was chromatographed over silica gel, eluting with a gradient of 0-10% [9:1 MeOH:NH3] in dichloromethane. The title compound was obtained as a colourless oil (348mg), m/z (API+) 185 [MH+].
Description 50 (S)-1-Amino-3-piperidin-1-yl-propan-2-ol (D50)
Figure imgf000055_0001
(R)-1-Azido-3-piperidin-1-yl-propan-2-ol (340mg) was dissolved in ethanol (25ml) and hydrogenated at 50 psi and room temperature in the presence of 10% Pd/C catalyst (350mg). After 2hrs the reaction mixture was filtered and evaporated. The title compound was obtained as a colourless oil (117mg), m/z (API+) 159 [MH+].
Description 51
(2R,S)-Methyl-1-[(R)-oxiranylmethyl]piperidine (D51)
Figure imgf000055_0002
Potassium hydride (527mg; 30% in oil) was weighed into an oven dried 3-necked flask and stirred in THF (5ml) under an inert atmosphere during the addition of a solution of (2R,S)-methylpiperidine (0.52ml) in THF (5ml). The reaction solution was stirred at room temperature for 2 hrs. S-(-)-Glycidyl nosylate (904mg) was then added dropwise as a solution in THF (5ml) and the reaction mixture stirred at room temperature for 16 hours. The reaction mixture was filtered under an inert atmosphere through Celite™ and the organic solution reduced to half volume at reduced pressure, m/z 156 (API+) [MH+].
Description 52
1-Azido-3-[(2R,S)-methyIpiperidin-1-yl]-propan-(2R)-ol (D52)
Figure imgf000055_0003
To the product solution from Description 51 was added lithium azide (5.34ml, 20% solution in water) and the reaction mixture heated at 70°C for 16 hours. The solvent was then removed at reduced pressure and the residue was partitioned between EtOAc and
NaHCO3 solution. The organic solution was dried (MgSO4), and evaporated. The residual oil was chromatographed over silica gel, eluting with a gradient of 0-10% [9:1 MeOH:NH3] in dichloromethane. The title compound was obtained as a colourless oil (326mg), m/z 199 (API+) [MH+].
Description 53
1-Amino-3-[(2R,S)-methylpiperidin-1-yl)-propan-(2S)-ol (D53)
Figure imgf000056_0001
1-Azido-3-[(2R,S)-methylpiperidin-1-yl]-propan-(2R)-ol (320mg) was dissolved in EtOH (25ml) and hydrogenated at 50 psi and room temperature in the presence of 10% Pd/C catalyst (350mg). After 2hrs the reaction mixture was filtered and evaporated. Title compound was obtained as a colourless oil (215mg), m/z 173 (API+) [MH+].
Description 54
(2R,6S)-Dimethyl-1 -[(R)-oxiranylmethyl]piperidine (D54)
Figure imgf000056_0002
Potassium hydride (860mg; 30% in oil) was weighed into an oven dried 3-necked flask and stirred in THF (5ml) under an inert atmosphere during the addition of (2R.6S)- dimethylpiperidine (0.75ml) as a solution in THF (5ml). The suspension was stirred at room temperature for 2 hrs. S-(-)-Glycidyl nosylate (1.13g) was then added dropwise as a solution in THF (5ml) and the reaction mixture stirred at room temperature overnight. The reaction mixture was filtered under an inert atmosphere through Celite™ and the organic solution evaporated to half volume at reduced pressure, m/z 170 (API+) [MH+].
Description 55
(R)-1-Azido-3-[(2R,6S)dimethylpiperidin-1 -yl]propan-2-ol (D55)
Figure imgf000056_0003
To the product solution from Description 54 was added lithium azide (5.63ml, 20% solution in water) and the reaction mixture heated at 70°C overnight. The solvent was then evaporated in vacuo and the solution partitioned between EtOAc and NaHCO3 solution. The organic solution was dried (MgSO4), and evaporated. The residual oil was chromatographed over silica gel, eluting with a gradient of 0-10% [9:1 MeOH:NH3] in dichloromethane. The title compound was obtained as a colourless oil (80mg), m/z 213 (API+) [MH+].
Description 56
(S)-1 -Amino-3-[(2R,6S)dimethylpiperidin-1 -yl)-propan-2-ol (D56)
Figure imgf000057_0001
(R)-1-Azido-3-[(2R,6S)dimethylpiperidin-1-yl]propan-2-ol (80mg) was dissolved in ethanol (25ml) and hydrogenated at 50 psi and room temperature in the presence of 10% Pd/C catalyst (80mg). After 2hrs the reaction mixture was filtered and evaporated. Title compound was obtained as a colourless oil (80mg).
Description 57
(2S)-Ethyl-1 -[(R)-oxiranylmethyl]piperidine (D57)
Figure imgf000057_0002
(S)-(+)-2-ethylpiperidine hydrochloride (1.00g, 6.69 mmol) (prepared by the method of J. Cymerman Craig and A. R. Pinder, J. Orq. Chem.. 1971, 36(23), 3648) was added portionwise to a stirred suspension of potassium hydride (2.05g, 30% in oil, 15.39mmol) in dry THF (45 ml) under argon at room temperature. The suspension was stirred for a further two hours. A solution of the (S)-glycidyl nosylate (1.73g, 6.69 mmol) in dry THF (10 ml) was then added dropwise and the resulting mixture stirred overnight. The suspension was filtered through Celite™ and the filtrate evaporated to half-volume under reduced pressure to yield a solution of the title compound.
Description 58
1 -Azido-3-[(2S)-ethylpiperidin-1 -yl]-propan-(2R)-ol (D58)
Figure imgf000058_0001
A 20% solution of lithium azide in water (8.2ml, 33.4 mmol) was added to the solution of the product from Description 57 and the mixture stirred at 70° overnight. The cooled solution was evaporated under reduced pressure and the residue partitioned between ethyl acetate and saturated sodium hydrogen carbonate solution. The organic layer was washed with further saturated sodium hydrogen carbonate solution and dried over MgSOφ Removal of the solvent gave an oil which was chromatographed on silica gel. Elution with CHCI3 followed by 10% MeOH in CHCI3 afforded the title product as a yellow oil (500mg, 35%). 1H NMR δ(CDCI3) 0.89 (3H, t, J=7 Hz), 1.34-1.69 (9H, overlapping m), 2.1-2.25 (2H, overlapping m), 2.71 (1H, dd, J=12.4 and 10.4 Hz), 2.93 (1H, m), 3.19 (1H, dd, J=12.8 and 5.6 Hz), 3.37 (1 H, dd, J=12.8 and 4.0Hz), 3.85 (1 H, m) ppm.
Description 59
1-Amino-3-[(2S)-ethylpiperidin-1-yl)-propan-(2S)-ol (D59)
Figure imgf000058_0002
Hydrogenation of the azide from Description 58 (500mg, 2.36 mmol) over 10% palladium on charcoal (100mg) in methanol (25ml) at ambient temperature and pressure for 3 hours and subsequent removal of the catalyst by filtration through celite gave, after removal of the solvent under reduced pressure, the crude amine (2.36 mmol) which was used without further purification.
Description 60
(S)-1 -Azido-3-(2-methylpyrrolidin-1 -yl)propan-2-ol (D60)
Figure imgf000058_0003
The title compound was prepared from 2-methylpyrrolidine (155mg;1.82mmol) and (R)-(-)- glycidyl nosylate (429mg;1.6mmol) using the method outlined in Description 1 (76mg; 25% over two steps). MH+ 185.
Description 61 (R)-1-Amino-3-(2-methylpyrrolidin-1-yl)propan-2-ol (D61)
Figure imgf000059_0001
The title compound was prepared from (S)-1-azido-3-(2-methylpyrrolidin-1-yl)propan-2-ol (D60) (63mg; 0.34mmol) using the method outlined in Description 2 (50mg; 92%). MH+ 159.
Description 62
(S)-1 -Azido-3-(3-methylpiperidin-1 -yl)propan-2-ol (D62)
Figure imgf000059_0002
The title compound was prepared from 3-methylpiperidine (366mg; 3.7mmol) and (R)-(-)- glycidyl nosylate (871 mg; 3.4mmol) using the methods outlined in Description 1 (220mg; 33% over two steps).
Description 63
(R)-1-Amino-3-(3-methylpiperidin-1-yl)propan-2-ol (D63)
Figure imgf000059_0003
The title compound was prepared from (S)-1-azido-3-(3-methylpiperidin-1-yl)propan-2-ol (D62) (160mg; 0.81 mmol) using the method outlined in Description 2 (130mg; 94%).
Description 64.
2-Oxiranylmethyl-isoindole-1 ,3-dione (D64)
Figure imgf000059_0004
To a stirred solution of phthalimide (735mg) in THF (30ml) was added triphenylphosphine (1.310g) and (S)-glycidol (0.38ml). This solution was cooled using an external ice bath for the dropwise addition of diethylazodicarboxyate (0.8ml). The reaction mixture was stirred at room temperature overnight. The reaction mixture was then concentrated, and stirred in diethyl ether for 2h. White precipitate was filtered and liquor was evaporated. The residual yellow oil was chromatographed over silica gel, eluting with ethyl acetate/hexane (1 :1). Title compound was obtained as a white solid (815mg), m/z 204 [MH+].
Description 65.
2,6-Diethylpyridine (D65)
Figure imgf000060_0001
2,6-Diacetylpyridine (2g) was dissolved in diethyleneglycol (50ml) with hydrazine monohydrate (3.6ml). The reaction mixture was heated at 170°C for 30 min. The reaction mixture was then cooled to room temperature for the addition of potassium hydroxide (3.1g), then heated at 200°C for 2h when the reaction mixtue lost all colour. The reaction mixture was then cooled to room temperature and poured onto water. The mixture was extracted with ether, organics combined, washed with brine, dried (MgSO4) and concentrated to give desired product (1.5g, 93%), δπ (CDCI3) 1.29 (6H, t, J 7.6Hz), 2.76- 2.82 (4H, q, J 7.6Hz), 6.96 (2H, d, J 7.6Hz), 7.50 (1 H, t, J 7.6Hz).
Description 66.
2,6-Diethylpiperidine (D66)
Figure imgf000060_0002
2,6-Diethylpyridine (D65) was hydrogenated in acetic acid with platinum oxide overnight. The reaction mixture was filtered through celite, washed with a small amount of AcOH and basified with KOH and K2CO3 to pH 9. The emulsion was extracted with diethyl ether, dried (MgSO4) and concentrated to give the desired product (1g, 70%), δ|-| (CDCI3) 0.91 (6H, m), 1.06 (2H, m), 1.41 (1 H, m), 1.44 (4H, m), 1.68 (2H, m), 1.70 (1H, m), 2.44 (2H, m). Description 67.
2-[(R)-3-(2,6-Diethylpiperidin-1-yl)-2-hydroxy-propyI]-isoindole-1 ,3-dione (D67)
Figure imgf000061_0001
2,6-Diethylpiperidine (D66) (1g) and 2-oxiranyImethylisoindole-1 ,3-dione (D64) (1.4g) were heated together at 70°C overnight. After cooling to room temperature the crude mixture was chromatographed over silica gel, eluting with a gradient of 0-10% [9:1 MeOH:NH3] in dichloromethane. Title compound was obtained as an oil (90mg), m/z 345 [MH+]
Description 68.
(S)-1 -Amino-3-(2,6-diethylpiperidin-1 -yl)-propan-2-ol (D68)
Figure imgf000061_0002
2-[(R)-3-(2,6-Diethylpiperidin-1-yl)-2-hydroxypropyl]-isoindole-1,3-dione (D67) (90 mg) was stirred in ethanol (2ml) with hydrazine monohydrate (0.06ml) overnight. White precipitate was removed by filtration and liquor concentrated. The crude mixture (70mg) containing the title compound was progressed without purification.
Description 69.
2-[(R)-3-[(2R,6S)-Dimethylpiperidin-1 -yl]-2-hydroxy-propyl]-isoindole-1 ,3-dione (D69)
Figure imgf000061_0003
2,6-Dimethylpiperidine was reacted with 2-oxiranylmethylisoindole-1 ,3-dione (D64) by the procedure of Description 67. The title compound was obtained as a colourless oil.
Description 70.
(S)-1-Amino-3-[(2R,6S)-dimethylpiperidin-1-yl]-propan-2-ol (D70)
Figure imgf000062_0001
2-[(R)-3-[(2R,6S)-Dimethylpiperidin-1-yl]-2-hydroxy-propyl]-isoindole-1 ,3-dione (D69) was treated with hydrazine hydrate according to the procedure of Description 68 to yield the title compound as a colourless oil, which was identical to the product of Description 56.
Description 71. Quinoline-5-sulfonyl chloride (D71)
Figure imgf000062_0002
(a) Thionyl chloride (2.1ml) was added dropwise to water (12.5ml) at 5°C. This mixture was allowed to warm to room temperature and stirred for 16h. Copper I chloride (10mg) was then added and the resulting yellow solution coofed to 0°C. (b) Concentrated hydrochloric acid (6.75ml) was cool d to 0°C for the portionwise addition of 5-amino quinoline (1g). This was allowed to warm slightly between additions, when the reaction mixture turned red/orange. After complete addition, the reaction mixture was cooled to -5°C for the dropwise addition of a solution of NaNO2 (0.5g) in water (2ml). After complete addition and at -5°C, the resulting mixture was added slowly to the cooled thionyl chloride/CuCI mixture from part (a).. A solid precipitated and the mixture was stirred at 0°C for 1.5h. The brick red solid was filtered and washed with water (300mg), δ|-| (CDCI3) 7.71 (1H, m), 7.88 (1H,m), 8.44 (1H,m), 8.52 (1H,m), 9.1-9.2 (2H, m).
Description 72.
5-Methoxynaphthalen-1 -ylamine (D72)
Figure imgf000063_0001
5-Amino-1-naphthol (3.0g) was dissolved in dry DMF (75ml) and cooled to 5°C under an atmosphere of argon. Sodium hydride (0.828g, 60% dispersion in oil)was added portionwise to the stirred, cooled sollution over a period of 15 minutes. A solution of methyl iodide (1.17 ml) in dry DMF (5ml) was then added dropwise to the stirred, cooled suspension. The resulting suspension was then stirred at room temperature for 16 hours. The reaction solution was then partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic solution was washed with brine, dried (MgSO4) and evaporated. Crystallisation from ethyl acetate/hexane provided the pure title compound as black needles (1.34g), δH (d6-DMSO) 3.92 (3H,s), 5.61 (2H, broad s), 6.69 (1H, d), 6.88 (1 H, d), 7.17 (1H, t), 7.29 (1 H, t), 7.37 (1H, d), 7.6 (1 H, d).
Description 73.
5-Methoxynaphthalene-1-sulfonyl chloride (D73)
Figure imgf000063_0002
5-Methoxynaphthalen-1-ylamine (D72) was converted to the title compound by the procedure of R. V. Hoffman, Organic Syntheses, 60, 121. Silica gej column chromatography, eluting with a gradient of 0 to 30% ethyl acetate in hexane gave the title compound as a pale yellow solid, δπ (CDCI3) 4.09 (3H, s) 7.0 (1 H, d), 7.59 (1H, t), 7.72 (1 H, t), 8.35 (1H, d), 8.4 (1 H, d), 8.72 (1H, d).
Description 74.
5-Cyanonaphthalene-1-sulfonyl chloride (D74)
Figure imgf000063_0003
5-Cyanonaphthalen-1-ylamine was converted to the title compound by the procedure of R. V. Hoffman, Organic Syntheses, 60, 121. Silica gel column chromatography, eluting with a gradient of 0 to 30% ethyl acetate in hexane gave the title compound as a pale yellow solid, δH (d6-DMSO) 7.67-7.78 2H, 2 x t), 8.10 (2H, d), 8.18 (1 H, d), 9.21 (1H, d) Description 75.
4-Cyanonaphthalene-1-sulfonyl chloride (D75)
Figure imgf000064_0001
4-Cyanonaphthalen-1-ylamine was converted to the title compound by the procedure of R. V. Hoffman, Organic Syntheses, 60, 121. Silica gel column chromatography, eluting with a gradient of 0 to 50% ethyl acetate in hexane gave the title compound as a white solid, δH (d6-DMSO) 7.70 (1H, t), 7.78(1 H, t), 8.06 (1H, d), 8.11 (2H, d), 9.0 (1H, d).
Description 76.
4-Bromonaphthalene-1-sulfonyl chloride (D76)
Figure imgf000064_0002
4-Bromonaphthalen-1-ylamine was converted to the title compound by the procedure of R. V. Hoffman, Organic Syntheses, 60, 121. Silica gel column chromatography, eluting with a gradient of 0 to 30% ethyl acetate in hexane gave the title compound as a pale orange solid, δH (d6-CDCI3) 7.80 (1H, t), 7.88 (1H, t), 7.96 (1H, d), 8.20 (1H, d), 8.48 (1H, d), 8.83 (1 H, d).
Description 77.
4-Fluoronaphthalene-1-sulfonyl chloride (D77)
Figure imgf000065_0001
1-Fluoronaphthalene (1.262 ml) was added dropwise over a period of 20 min to an ice- cooled, stirred solution of chlorosulphonic acid (2.3ml). The mixture was stirred for an additional 30min at 5°C and 3h at room temperature. The mixture was then poured onto ice and extracted twice with ethyl acetate. The organic solution was washed with water, brine, dried (MgSO4) and evaporated. The residue was chromatographed over silica gel, eluting with a gradient of 10 to 30% ethyl acetate in hexane. The title compound was obtained as a pale yellow solid (0.86g), δH (d6-CDCI3) 7.27 (1H, dd, J 8.6, 9.1Hz), ), 7.77 (1H, ddd, J 0.8, 7.2, 8.2Hz), 7.89 (1H, ddd, J 1.3, 7.1, 8.6Hz), 8.29 (1 H, d, J 8.4Hz), 8.39 (1H, dd, J 8.4, 5.1 Hz), 8.80, (1H, ddd, J 0.9, 0.9, 8.7Hz).
Example 1
Naphthalene-1 -sulfonic acid r(R)-2-amino-3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-propyπ- amide
Figure imgf000065_0002
Naphthalene-1 -sulfonic acid [(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-2-hydroxy- propylj-amide was prepared by the following procedure: (S)-1-Amino-3-piperidin-1- ylpropan-2-ol (D50; 117mg) was dissolved in dichloromethane (6ml) and 1- naphthylsulfonylchloride (185mg) and triethylamine (0.11ml) were added. The reaction mixture was stirred overnight, diluted with dichloromethane and washed with NaHCO3 solution and brine. The organic solution was dried (MgSO4), and evaporated. The residual oil was chromatographed over silica gel, eluting with a gradient of 0-10% [9:1 MeOH:NH3] in dichloromethane. The compound was obtained as a colourless oil (143mg), m/z (API+) 349 [MH+].
A stirred solution of naphthalene-1 -sulfonic acid [(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1- yl)-2-hydroxy-propyl]-amide (2.26g, 6.01 mmol) in dry DCM (100ml) under argon was treated with 4-nitrobenzenesulphonyl chloride (2.00g, 9.02mmol) and triethylamine (1.68ml, 12.02mmol) and stirred for 2 hours. The solvent was removed by evaporation. The crude intermediate was then dissolved in dry DMF (24ml) and treated with sodium azide (0.78g, 12.02mmol). The mixture was stirred at room temperature for 24 hours and then diluted with EtOAc, washed with water (6X), dried and evaporated to afford crude product. Chromatography on silica gel, eluting with 2% (10% NH3 in MeOH) in DCM, gave the azide as a yellow oil (0.88g, 37%). MS APCI (+ve ion) 402 (MH+).
This azide in MeOH (30ml) was hydrogenated over 10% palladium on charcoal at atmospheric pressure and temperature for 18 hours. The mixture was filtered through celite and the filtrate evaporated to afford the title compound as a pale foam (0.92g).
Example 2 -{(R)-2-((2S.6R)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)-methvπ- ethyll-acetamide
Figure imgf000066_0001
The amine from example 1 (50mg, 0.13mmol) in DCM (1.5ml) was treated with 1- hydroxybenzotriazole hydrate (7mg), 1-(3-dimethylaminopropyl)-3-ethyIcarbodiimide hydrochloride (21 mg) and acetic acid (8mg, 0.13mmol) and shaken overnight. The reaction mixture was shaken with sat. sodium hydrogen carbonate solution (1 ml) and the organic layer applied to a silica gel column. Gradient elution with 5% - 10% (10% NH3 in MeOH) in DCM gave the title compound as a foam (40mg, 74%). MS electrospray (+ve ion) 418 (MH+); (-ve ion) 416 (M-H). 1H NMR (CDCI3) δ 0.95 (6H, overlapping d), 1.1 - 1.7 (6H, overlapping m), 1.84 (3H, s), 2.40 (2H, br m), 2.47 (2H, d, J = 7.6Hz), 2.94 (1 H, dd, J = 12.4 and 6.0Hz), 3.12 (1H, dd, J = 12.4 and 4.8Hz), 3.67 (1H, m), 5.98 (1 H, br), 7.53 (1H, dd, J = 8.0 and 8.0Hz), 7.61 (1 H, dd, J = 8.0 and 8.0Hz), 7.69 (1H, dt, J = 7.2, 7.2 and 1.6Hz), 7.93 (1 H, d, 8.0Hz), 8.05 (1H, d, J = 8.4Hz), 8.23 (1H, dd, 7.2 and 1.2Hz), 8.69 (1 H, d, 8.8Hz) ppm.
The following compounds were prepared by the same method:-
Figure imgf000066_0002
Table 1
Figure imgf000066_0003
Figure imgf000067_0001
Example 21 Λ/-r(R)-1-(Benzenesulfonylamino-methyl)-2-((2S.6R)-2.6-dimethyl-piperidin-1-yl)-ethvn-4- methanesulfonyl-benzamide
Figure imgf000068_0001
A solution of 2-[(R)-3-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-2-hydroxy-propyl]-isoindole- 1 ,3-dione (2.45g, 7.75mmol) (D69) in ethanol (150ml) was treated with hydrazine hydrate (1.88ml, 38.8mmol) and stirred overnight at room temperature under argon. The white precipitate was filtered off and the filtrate evaporated to afford a gum which was dissolved in DCM (50ml) and treated with di-f-butyl dicarbonate (2.39g, 10.97mmol) and dimethylaminopyridine (50mg). Stirred at room temperature for 3 days, washed with water (1X), dried over MgSO4 and the solvent removed by evaporation to afford a crude product. Chromatography on silica gel, eluting with 5% (10% NH3 in MeOH) in DCM, gave the N- BOC derivative as a white solid (1.35g, 65%). MS electrospray (+ve ion) 287 (MH+), 231 (MH+-butene).
The alcohol was converted to the azide by treatment with 4-nitrobenzenesulphonyl chloride and sodium azide as outlined in example 1. Hydrogenation as described in example 1 gave the amine as a yellow gum which was used without further purification.
A solution of the amine (1.25mmol) in DCM was acylated with 4- methanesulphonylbenzoic acid as described in example 2. Chromatography on silica gel afforded the amide as a white solid. MS electrospray (+ve ion) 468 (MH+), 412 (MH+ - butene).
A solution of the t-butyl ester (47mg, 0.1 mmol) in trifluoroacetic acid (1.9ml) and water (0.1ml) was stirred for 2 hours and the volatile components removed under reduced pressure. The residue was re-evaporated from toluene (2X) and dissolved in DCM (1.5ml) and treated with triethylamine (70ul, O.δmmol) followed by benzenesuphonyl chloride (26mg, 0.15mmol). Stirring was continued overnight and saturated sodium hydrogen carbonate solution (1ml) added. The organic layer was chromatographed on silica gel eluting with 5% - 10% (10% NH3 in MeOH) to afford the title compound as a colourless gum (50mg). MS electrospray (+ve ion) 508 (MH+); (-ve ion) 506 (M-H). 1H NMR (CDCI3) δ 1.04 (3H, br d), 1.10 (3H, br d), 1.2 - 1.8 (6H, overlapping br m), 2.56 (2H, br m), 2.73 (2H, br m), 3.08 (3H, s), 3.16 (1 H, br m), 3.33 (1H, br d, J = 13Hz), 3.87 (1 H, br m), ca. 7.55 (3H, overlapping m), 7.87 (2H, d, J = 7.6Hz), ca. 8.0 (4H, overlapping m) ppm. The following compounds were prepared by the same method:
Figure imgf000069_0001
Figure imgf000070_0003
Example 33
Naphthalene-1 -sulfonic acid [(R)-2-benzenesulfonylamino-3-((2S.6RV2.6-dimethyl- piperidin-1 -vD-propyll-amide
Figure imgf000070_0001
The amine from example 1 (70mg, 0.18mmol) in DCM (5ml) was treated with benzenesulphonyl chloride (106mg, 0.60mmol) and triethylamine (30ul, 0.21 mmol) and stirred overnight. The reaction mixture was washed with water, sat. sodium hydrogen carbonate solution (1ml) and brine and the organic layer applied to a silica gel column. Gradient elution with 1% - 5% (10% NH3 in MeOH) in DCM gave the title compound (44mgι 46%). MS APCI (+ve ion) 516 (MH+); (-ve ion) 514 (M-H).
The following compounds were prepared by the same method:-
Figure imgf000070_0002
Tab
Figure imgf000070_0004
Example 38
Naphthalene-1 -sulfonic acid r(R)-3-((2S.6RV2.6-dimethyl-piperidin-1-vn-2-(3-phenyl- ureido)-propyll -amide
Figure imgf000071_0001
The amine from example 1 (70mg, O.iθmmol) in DMF (5ml) was treated with phenylisocyanate (21 ul, 0.19mmol) and stirred overnight. The reaction mixture was washed with water, sat. sodium hydrogen carbonate solution (1ml) and brine and the organic layer applied to a silica gel column. Gradient elution with 1% - 5% (10% NH3 in MeOH) in DCM gave the title compound (46mg, 50%). MS APCI (+ve ion) 495 (MH+); (- ve ion) 493 (M-H).
The following compounds were prepared by the same method:-
Figure imgf000071_0002
Table 4
Figure imgf000071_0003

Claims

Claims
A compound of formula (I):
Figure imgf000072_0001
(I)
or a salt, solvate or a physiologically functional derivative thereof, wherein: (i) R1 and R2 are independently:
(a) a group -(CR11R12)n-A wherein R11 and R12 are independently hydrogen or C-i- C6 alkyl, n is 0 or 1 and A is hydrogen, optionally substituted C^Ce alkyl, optionally substituted aryl or optionally substituted arylC1-C4 alkyl, wherein R1 and R2 are not both hydrogen; or
(b) a group
Figure imgf000072_0002
wherein m is 1 , 2, 3, 4 or 5 and R is hydrogen or C^Ce alkyl; or
(c) a group
Figure imgf000072_0003
wherein p is 1 , 2, 3, 4 or 5, R >14 is hydrogen or C^Ce alkyl, and B is an optionally substituted aryl;
or (ii) R1 and R2, together with the nitrogen atom to which they are attached, form a group:
Figure imgf000073_0001
wherein Q is an optionally substituted 4-, 5-, 6- or 7-membered saturated ring, wherein one or more of the carbon atoms of the saturated ring is optionally replaced by a heteroatom independently selected from N, O and S, and R15, R16, R17and R18 are independently hydrogen or Cι-C6 alkyl;
RJ is
•00, \ wherein Y is Cι-C2 alkylene, C2 alkenylene or C2 alkynylene, q is 0 or 1 , and Z is a 5- to 7-membered optionally substituted monocyclic aromatic ring system or 6- to 11 -membered optionally substituted bicyclic aromatic ring system;
R4 and R5 are both hydrogen, or one of R4 and R5 is hydrogen and the other is: (a) -SO2R19 wherein R19 is a 5- to 7- membered optionally substituted monocyclic aromatic ring system or a 6- to 11- membered optionally substituted bicyclic aromatic ring system; or (b) -XR20 wherein X is -CO(CH2)r- (wherein r is 0, 1 , 2, 3 or 4) or -CONH- wherein R20 is hydrogen, C-|-C6 alkyl or a 5- to 7- membered optionally substituted monocyclic aromatic ring system or a 6- to 11- membered optionally substituted bicyclic aromatic ring system;
R6 is independently selected from hydrogen, Cι-C6alkyl, C3-C6cycloalkyl, C3- C6cycloalkylCι-C6alkyl, aryl and arylCι-C4 alkyl; and
R7, R8, R9 and R10 are independently selected from hydrogen, Cι-C6 alkyl, C3-C6 cycloalkyl, aryl or arylC -C alkyl; or R7 and R8 together form a C3-C6 cycloalkyl group, and/or R9 and R10 together form a C3-C6 cycloalkyl group.
2. A compound as claimed in claim 1 , having the following stereochemical configuration:
Figure imgf000074_0001
3. A compound as claimed in claim 1 or claim 2, wherein R1 and R2 are independently selected from optionally substituted Cι-C6 alkyl.
4. A compound as claimed in claim 3, wherein the Cι-C6 alkyl is substituted by one, two or three groups selected from: halogen, Chal y!, C^^alkoxy, halθd-4alkyl, haloC^alkoxy, C-|_4alkylsulfonamidoC<|_4alkyl, C-^alkylamidoC-^alkyl, aryl, arylC-μ 4alkyl, a group R21CON(R22)(CH2)r, R21R22NCO(CH2)r, R21R22NSO2(CH2)r or R21SO2NR22(CH2)r (where each of R21 and R22 independently represents a hydrogen atom or a C-|_4alkyl group or where appropriate R21R22 forms part of a C3_6azacyloalkane or C3_g(2-oxo)azacycloalkane ring and r represents zero or an integer from 1 to 4).
5. A compound as claimed in claim 1 or claim 2, wherein R1 and R2 together with the nitrogen atom to which they are attached are linked to form a 4-, 5-, 6- or 7-membered heterocyclic ring, wherein the sole heteroatom is the nitrogen atom to which R1 and R2 are attached, said ring being optionally substituted by one, two or three groups selected from the group consisting of: halogen, Chalky], C^alkoxy, haloc<|-4alkyl, haloC^^alkoxy, Cι_4alkylsulfonamidoC<|_4alkyl, C^alkylamidoC^alkyl, aryl, arylC-|_4alkyl, a group R21CON(R22)(CH2)r, R21R22NCO(CH2)r, R21R22NSO2(CH2)r or R21SO2NR22(CH2)r (where each of R21 and R22 independently represents a hydrogen atom or a C-^alkyl group or where appropriate R21R22 forms part of a C3_6azacyloalkane or C3_Q(2- oxo)azacycloalkane ring and r represents zero or an integer from 1 to 4), said ring being further optionally fused to a C5-C7 alicyclic or 5- or 6-membered aromatic or heteroaromatic ring.
6. A compound as claimed in claim 1 or claim 2, wherein R1 and R2 together with the nitrogen atom to which they are attached are linked to form a 5- or 6-membered ring, wherein one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from N, O and S, said ring being optionally substituted by one, two or three groups selected from the group consisting of: halogen, C-i.øalkyl, C^alkoxy, haloc -4alkyl, haloC-^alkoxy, C.|_4alkylsulfonamidoC-|_4alkyl, C^^alkylamidoC^ 4alkyl, aryl, arylC-|_4alkyl, a group R21CON(R22)(CH2)r, R21R 2NCO(CH2)r, R21R22NSO2(CH2)r or R 1SO2NR22(CH2)r (where each of R21 and R22 independently represents a hydrogen atom or a C-|_4alkyl group or where appropriate R21R22 forms part of a C3_ρazacyloalkane or C3_6(2-oxo)azacycloalkane ring and r represents zero or an integer from 1 to 4), said ring being further optionally fused to a C5-C7 alicyclic or 5- or 6- membered aromatic or heteroaromatic ring.
7. A compound as claimed in claim 1 or claim 2, wherein R1 and R2 together with the nitrogen atom to which they are attached are linked to form a 5- or 6-membered heterocyclic ring, wherein the sole heteroatom is the nitrogen atom to which R1 and R2 are attached, said ring being optionally substituted by one or more groups independently selected from optionally substituted Cι-C6 alkyl and optionally substituted C3-C6 cycloalkyl, more preferably by one or more groups independently selected from Cι-C alkyl, most preferably methyl, ethyl or isopropyl.
8. A compound as claimed in claim 1 , wherein R1 and R2, together with the nitrogen atom to which they are linked, form: azetidine, azepine, pyrrolidine, imidazolidine, piperidine, morpholine, thiomorpholine or piperazine, all of which being optionally substituted by one, two or three groups selected from the group consisting of: halogen, C-|_6alkyl, C-|_4alkoxy, haloc -4alkyl, haloC-|_4alkoxy, C-|_4alkylsulfonamidoC-ι_4alkyl, C-|_4alkylamidoC-|_4alkyl, aryl, arylC-|_4alkyl, a group R21CON(R22)(CH2)r, R21R 2NCO(CH2)r, R21R22NSO2(CH2)r or R21SO2NR22(CH2)r (where each of R21 and R22 independently represents a hydrogen atom or a C^alkyl group or where appropriate R21R22 forms part of a C3_eazacyloalkane or C3_6(2-oxo)azacycloalkane ring and r represents zero or an integer from 1 to 4).
9. A compound as claimed in claim 1 , wherein R1 and R2 together with the nitrogen atom to which they are attached are linked to form a pyrrolidinyl ring, said ring being optionally substituted by one or more groups independently selected from optionally substituted C1-C4 alkyl, preferably methyl, ethyl or isopropyl.
10. A compound as claimed in claim 9, wherein the pyrrolidinyl ring formed by R1 and R2 together with the nitrogen atom to which they are attached is substituted by one or more C1-C4 alkyl groups, preferably methyl, ethyl or isopropyl groups, preferably at the 2- and/or 5-positions, more preferably at the 2-position.
11. A compound as claimed in claim 1 , wherein R1 and R2, together with the nitrogen atom to which they are attached are linked to form a piperidinyl ring, said ring being optionally substituted by one or more groups independently selected from optionally substituted Cι-C alkyl, preferably methyl or ethyl.
12. A compound as claimed in claim 11 wherein the piperidinyl ring formed by R1 and R2 together with the nitrogen atom to which they are attached is substituted by one or more methyl or ethyl groups, preferably at the 2- and 6-positions.
13. A compound as claimed in claim 11 wherein the piperidinyl ring formed by R1 and R2 together with the nitrogen atom to which they are attached is substituted by two methyl groups, preferably at the 2- and 6- positions.
14. A compound as claimed in any of claims 1-13, wherein q is 0.
15. A compound as claimed in any of claims 1-14, wherein Z is substituted by 1 , 2 or 3 groups independently selected from: -hal, -R23, -OR24, -C(O)OR25, -CN, -NO2, - NR26R27, -C(O)NR28R29, -NR30C(O)R31, -C(O)R32, -C(NR33)NR34R35, -C(NOR36)R37, and C-|_Qalkylsulphonyl; wherein R23 is Cι-C6 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylC1-C alkyl, aryl, aryloxy or arylCι-C4 alkyl, all of which being optionally substituted by one or more groups independently selected from hal, C.,-C6 alkyl, -OR24, -COOR25 -CN, -NO2 and -NR26R27, wherein R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36 and R37 are independently selected from hydrogen and Cι-C6 alkyl.
16. A compound as claimed in any of claims 1-15, wherein Z is a 5- to 7-membered optionally substituted monocyclic aromatic ring system.
17. A compound as claimed in claim 16, wherein Z is phenyl, optionally substituted by one or more groups independently selected from -hal, -R23, -CF3, -C-i-Cβalkylsulphonyl, -
OR24, -COOR25, -CN, -NO2 or -NR26R27, wherein R23, R24, R25, R26 and R27 are as defined in claim 14.
18. A compound as claimed in any of claims 1-15, wherein Z is a 8- to 10-membered optionally substituted bicyclic aromatic ring system.
19. A compound as claimed in claim 18, wherein Z is naphthyl, naphthyridinyl, quinolinyl, isoquinolyl, benzothienyl, chromanyl, chromenyl, imidazoleisothiazolyl, benzothiadiazolyl or benzofuryl.
20. A compound as claimed in claim 19, wherein Z is quinolinyl (preferably 5- quinolinyl), optionally substituted by one or more groups independently selected from - hal, -R23, -OR24, -COOR25, -CF3, -C<|-C6alkylsulphonyl, -CN, -NO2, and -NR 6R27, wherein R23, R24, R25, R26 and R27are as defined in claim 14.
21. A compound as claimed in claim 20, wherein Z is quinolinyl (preferably 5- quinolinyl), optionally substituted by one or more groups independently selected from -hal, -R23, -CF3, -Cι-C6alkylsulphonyl, -OR24, -COOR25, -CN, -NO2 or -NR26R27, wherein R23, R24, R25, R26 and R27 are independently selected from hydrogen and Cι-C6 alkyl.
22. A compound as claimed in any of claims 1-21 wherein R3 is phenyl or 5-quinolinyl.
23. A compound as claimed in any of claims 1-22, wherein one of R4 and R5 is hydrogen and the other is a group -COCH2R38, -COR38 or -CONHR38 wherein R38 is a 5- to 7- membered monocylic aromatic ring system or a 6- to 11- membered bicyclic aromatic ring system, said ring system being optionally substituted by one or two groups independently selected from hal, CF3, C^Cealkyl, Cι-C6alkoxy,-CN, Ci-Cealkylamido, Cι-C6alkanoyl and Cι-C6alkylsulphonyl.
24. A compound as claimed in any of claims 1-23, wherein R6 is selected from hydrogen, Cι-C6 alkyl, aryl and benzyl, optionally substituted by one or more groups independently selected from hal, Cι-C6 alkyl, hydroxy and Cι-C6 alkoxy.
25. A compound as claimed in any of claims 1-24, wherein R7, R8, R9 and R10 are hydrogen.
26. A compound of formula (la):
Figure imgf000077_0001
or a salt or solvate or a physiologically functional derivative thereof, wherein:
R39 and R40 are independently selected from C3-C6 alkyl, or
R39 and R40, together with the nitrogen atom to which they are attached, are linked to form a 5-, 6-, or 7- membered heterocyclic ring, wherein the sole heteroatom is the nitrogen atom to which R39 and R40 are attached, said heterocyclic ring being optionally substituted by one or more groups independently selected from Cι-C4 alkyl and C3-C6 cycloalkyl, and said heterocyclic ring being further optionally fused to a C6 alicyclic or aromatic ring, and said heterocyclic ring being further optionally bridged by a methylene group;
R41 is
H H J a wherein a is 0 or 1 , and Z1 is a 5- or 6-membered monocyclic aromatic ring system or a 6- to 10-membered bicyclic aromatic ring system, said ring system being optionally substituted by one or more groups independently selected from -hal, -R44, -OR45, -COOR46, -CN, - NO2, -NR47R48, wherein R44 is Cι-C4 alkyl or phenyl optionally substituted by one or more hal groups and R45, R46, R47 and R48 are independently selected from hydrogen and methyl, one of R42 and R43 is hydrogen and the other is a group -X1R49, wherein X^ is CONH- or - CO(CH2)b- wherein b is 0, 1 or 2, and R49 is a 5- to 6-membered monocylic aromatic ring system or a 6- to 10- membered bicyclic aromatic ring system, said ring system being optionally substituted by one, two or three groups independently selected from -hal, -R50, -OR51, -C(O)OR52, -CN, -NO2, -NR53R54, -C(O)NR55R56, -NR57C(O)R58, -C(O)R59, - C(NR60)NR61R62, -C(NOR63)R64, or Cι_6alkylsulphonyl, wherein R50 is Cι-C6 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylCι-C4 alkyl, aryl, aryloxy or arylCι-C alkyl, all of which being optionally substituted by one or more groups independently selected from hal, Cι-C6 alkyl, -OR51, -COOR52, -CN, -NO2 and -NR53R54; wherein R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63 and R64 are independently selected from hydrogen and Ci- Ce alkyl.
27. A compound as claimed in claim 26, having the following stereochemical configuration:
Figure imgf000078_0001
28. A compound as claimed in claim 1 which is: Ex 1 Naphthalene-1 -sulfonic acid [(R)-2-amino-3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)- propyl]-amide Ex 2 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-acetamide EX 3 A/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-benzamide
Ex 4 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-butyramide Ex 5 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-2-phenyl-acetamide Ex 6 Thiophene-2-carboxylic acid {(R)-2-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-1- [(naphthalene-1-sulfonylamino)-methyl]-ethyl}-amide Ex 7 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-4-methanesulfonyl-benzamide Ex 8 4-bromo-Λ/-{(R)-2-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 - sulfonylamino)-methyl]-ethyl}-benzamide
Ex 9 Naphthalene-2-carboxylic acid {(R)-2-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-1- [(naphthalene-1-sulfonylamino)-methyl]-ethyl}-amide Ex 10 Benzo[1 ,3]dioxole-5-carboxylic acid {(R)-2-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)-1 - [(naphthalene-1 -sulfonylamino)-methyl]-ethyl}-amide Ex 11 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-3-methoxy-benzamide Ex 12 3,5-Dichloro-Λ/-{(R)-2-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 - sulfonylamino)-methyl]-ethyl}-benzamide Ex 13 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-3-methanesulfonyl-benzamide Ex 14 A/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-2-methanesulfonyl-benzamide
Ex 15 Λ/-{(R)-2-((2R,6S)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-4-methoxy-benzamide Ex 16 Λ/-{(R)-2-((2R,6S)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-terephthalamic acid methyl ester Ex 17 4-Acetyl -Λ/-{(R)-2-((2R,6S)-2,6-dimethyl-piperidin-1 -yl)-1 -[(naphthalene-1 - sulfonylamino)-methyl]-ethyl}-benzamide Ex 18 4-cyano -Λ/-{(R)-2-((2R,6S)-2,6-dimethyl-piperidin-1-yl)-1 -[(naphthalene-1 - sulfonylamino)-methyl]-ethyl}-benzamide Ex 19 4-Acetylamino -Λ/-{(R)-2-((2R,6S)-2,6-dimethyl-piperidin-1 -yl)-1 -[(naphthalene-1 - sulfonylamino)-methyl]-ethyl}-benzamide
Ex 20 N-{(R)-2-((2R,6S)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(naphthalene-1 -sulfonylamino)- methyl]-ethyl}-2-(4-methanesulfonyl-phenyl)-acetamide Ex 21 Λ/-[(R)-1 -(Benzenesulfonylamino-methyl)-2-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)- ethyl]-4-methanesulfonyl-benzamide Ex 22 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-1-[(quinoline-5-sulfonylamino)- methyl]-ethyl}-4-methanesulfonyl-benzamide Ex 23 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(5-fluoro-2-methyl- benzenesulfonylamino)-methyl] -ethyl}-4-methanesulfonyl-benzamide Ex 24 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(4-methoxy- benzenesulfonylamino)-methyl]-ethyl}-4-methanesulfonyl-benzamide
Ex 25 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(naphthalene-2-sulfonylamino)- methyl]-ethyl}-4-methanesulfonyl-benzamide Ex 26 Λ/-[(R)-1 -[(5-Cyano-naphthalene-1 -sulfonylamino)-methyl]-2-((2S,6R)-2,6-dimethyl- piperidin-1-yl)-ethyl]-4-methanesulfonyl-benzamide Ex 27 Λ/-[(R)-1-(Benzenesulfonylamino-methyl)-2-((2S,6R)-2,6-dimethyl-piperidin-1-yl)- ethyl]-4-methoxy-benzamide Ex 28 A/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(quinoline-5-sulfonylamino)- methyl]-ethyl}-4-methoxy-benzamide Ex 29 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(5-fluoro-2-methyl- benzenesulfonylamino)-methyl] -ethyl}-4-methoxy-benzamide
Ex 30 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(4-methoxy- benzenesulfonylamino)-methyl]-ethyl}-4-methoxy-benzamide Ex 31 Λ/-{(R)-2-((2S,6R)-2,6-Dimethyl-piperidin-1 -yl)-1 -[(naphthalene-2-sulfonylamino)- methyl]-ethyl}-4-methoxy-benzamide Ex 32 Λ/-[(R)-1 -[(5-Cyano-naphthalene-1 -sulfonylamino)-methyl]-2-((2S,6R)-2,6-dimethyl- piperidin-1-yl)-ethyl]-4-methoxy-benzamide Ex 33 Naphthalene-1 -sulfonic acid [(R)-2-benzenesulfonylamino-3-((2S,6R)-2,6- dimethyl-piperidin-1-yl)-propyl]-amide Ex 34 Naphthalene-1 -sulfonic acid [(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)-2- (toluene-4-sulfonylamino) -propylj-amide Ex 35 Naphthalene-1 -sulfonic acid [(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-2-(4- methoxy-benzenesulfonylamino)-propyl]-amide
Ex 36 Naphthalene-1 -sulfonic acid [(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)-2-(4- methanesulfonyl-benzenesulfonylamino)-propyl]-amide Ex 37 Naphthalene-1 -sulfonic acid [(R)-2-(3,5-dichloro-benzenesulfonylamino)-3- ((2S,6R)-2,6-dimethyl-piperidin-1-yl)-propyl]-amide Ex 38 Naphthalene-1 -sulfonic acid [(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-2-(3- phenyl-ureido)-propyl] -amide Ex 39 Naphthalene-1 -sulfonic acid {(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)-2-[3-(4- methoxy-phenyl)-ureido]-propyl}-amide Ex 40 Naphthalene-1 -sulfonic acid {(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1-yl)-2-[3-(4- trifluoromethyl-phenyl)-ureido]-propyl}-amide
Ex 41 Naphthalene-1 -sulfonic acid {(R)-3-((2S,6R)-2,6-dimethyl-piperidin-1 -yl)-2-[3-(3- trifluoromethyl-phenyl)-ureido]-propyl}-amide Ex 42 Naphthalene-1 -sulfonic acid [(R)-2-[3-(2,3-dichloro-phenyl)-ureido]-3-((2S,6R)-2,6- dimethyl-piperidin-1-yl)-propyl]-amide or a salt or solvate or a physiologically functional derivative thereof.
29. A process for the preparation of a compound as claimed in any of claims 1-28, comprising the steps of:
(a) reacting a compound of formula (II)
Figure imgf000080_0001
wherein R1, R2, R4, R5, R6, R7, R8, R10 and R9 are as hereinbefore defined, with a compound of formula (III) R3SO2L (III)
wherein R3 is as hereinbefore defined and L is a suitable leaving group, such as, for example, a halogen, preferably chlorine; or
(b) converting a compound of formula (IV)
Figure imgf000081_0001
(IV)
wherein R1, R2, R3, R6, R7, R8, R9 and R10 are as defined for formula (I); and thereafter optionally for process (a) or process (b):
• converting a compound of formula (I) into another compound of formula (I); or
• removing any protecting groups; or
• forming a pharmaceutically acceptable salt, solvate or a physiologically functional derivative thereof.
30. A compound as claimed in any of claims 1-28 for use in therapy.
31. A compound as claimed in any of claims 1-28 for use in treating a disorder mediated by GlyTI .
32. A compound as claimed in claim 31 , wherein the disorder is a psychosis, including schizophrenia, dementia and attention deficit disorders, particularly schizophrenia.
33. A method of treating a mammal, including a human, suffering from or susceptible to a disorder mediated by GlyTI , which comprises administering an effective amount of a compound as defined in any of claims 1-28.
34. A method as claimed in claim 33, wherein the disorder is psychosis, including schizophrenia, dementia and attention deficit disorders, particularly schizophrenia.
35. Use of a compound as defined in any of claims 1-28 in the preparation of a medicament for the treatment of a disorder mediated by GlyTI .
36. Use as claimed in claim 35, wherein the disorder is psychosis, including schizophrenia, dementia and attention deficit disorders, particularly schizophrenia.
7. A pharmaceutical composition comprising a compound as claimed in any of claims-28 and at least one pharmaceutically acceptable carrier, diluent or excipient.
PCT/EP2004/013052 2003-11-18 2004-11-16 Glyt1 transporter inhibitors Ceased WO2005049023A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0326840.6 2003-11-18
GBGB0326840.6A GB0326840D0 (en) 2003-11-18 2003-11-18 Compounds

Publications (1)

Publication Number Publication Date
WO2005049023A1 true WO2005049023A1 (en) 2005-06-02

Family

ID=29764010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/013052 Ceased WO2005049023A1 (en) 2003-11-18 2004-11-16 Glyt1 transporter inhibitors

Country Status (2)

Country Link
GB (1) GB0326840D0 (en)
WO (1) WO2005049023A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006000222A3 (en) * 2004-06-24 2006-06-29 Lundbeck & Co As H The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
US8420670B2 (en) 2007-08-22 2013-04-16 Abbott Laboratories 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
CN103209964A (en) * 2010-08-13 2013-07-17 Abbvie德国有限责任两合公司 Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8563617B2 (en) 2009-02-16 2013-10-22 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8642587B2 (en) 2009-02-16 2014-02-04 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
US8653100B2 (en) 2008-04-01 2014-02-18 Abbvie Inc. Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586942B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CN107805223A (en) * 2017-10-30 2018-03-16 广东莱佛士制药技术有限公司 A kind of synthetic method of the sulfonic acid chloride of quinoxaline 5

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055478A1 (en) * 2001-12-21 2003-07-10 Smithkline Beecham P.L.C. Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055478A1 (en) * 2001-12-21 2003-07-10 Smithkline Beecham P.L.C. Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006000222A3 (en) * 2004-06-24 2006-06-29 Lundbeck & Co As H The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
US8420670B2 (en) 2007-08-22 2013-04-16 Abbott Laboratories 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8957089B2 (en) 2008-04-01 2015-02-17 AbbVie Deutschland GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8653100B2 (en) 2008-04-01 2014-02-18 Abbvie Inc. Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US9096619B2 (en) 2009-02-16 2015-08-04 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8563617B2 (en) 2009-02-16 2013-10-22 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8642587B2 (en) 2009-02-16 2014-02-04 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
US9067871B2 (en) 2009-02-16 2015-06-30 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9238619B2 (en) 2010-08-13 2016-01-19 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9227930B2 (en) 2010-08-13 2016-01-05 Abbvie Inc. Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
CN103209964A (en) * 2010-08-13 2013-07-17 Abbvie德国有限责任两合公司 Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586942B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
CN107805223A (en) * 2017-10-30 2018-03-16 广东莱佛士制药技术有限公司 A kind of synthetic method of the sulfonic acid chloride of quinoxaline 5

Also Published As

Publication number Publication date
GB0326840D0 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
WO2005049023A1 (en) Glyt1 transporter inhibitors
US20050267152A1 (en) Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
MXPA05000196A (en) 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough.
WO2005058882A1 (en) Compounds having morpholinyl and piperidinyl groups for use as glyt1 and glyt2 inhibitors
WO2005058885A2 (en) Piperidine derivatives and their use as glycine transporter inhibitors
WO2005058317A1 (en) Glycine transporter-1 inhibirors
EP1833811B1 (en) Oxygen containing heterocycles as glycine transporter inhibiting compounds
EP1910311A2 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
EP1858869A1 (en) Acylated piperidines as glycine transporter inhibitors
EP2041082B1 (en) Pyrrolidine derivatives having activity at the glyt1 transporter
US20100216837A1 (en) Glycine transport inhibitors
US20090221577A1 (en) Compounds having morpholinyl and piperidinyl groups for use as glyt1 inhibitors
US20090286828A1 (en) 2-amino-1-phenylethylcarboxamide derivatives
US20090253700A1 (en) N-&#39;4-4(4-morpholinyl) phenyl!- &#39;(4-piperidinyl) methyl! carboxamide derivatives and their use as glycine transporter inhibitors
US20100016374A1 (en) Compounds Which Inhibit the Glycine Transporter and Uses Thereof
US20090227629A1 (en) Compounds having activity at the glycine transporter glyt1 and uses thereof
WO2006002956A1 (en) Piperidine derivatives and their use as glycine transporter inhibitors
US20090318447A1 (en) N-[6-(4-morpholinyl)-3-pyridinyl]-2-(tetrahydro-2h-pyran-4-yl)-n-[(1--4-piperidinyl) methyl] acetamide derivatives and related compounds as glyt1 transport inhibitors for the treatment of neurological disorders such as schizophrenia
US20110009440A1 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
EP1858868A1 (en) Compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase